What we are asked, and what the analyses answer

Can this model be used outside the trust where it was built?

Not as it stands. It was built and tested in a single NHS trust, with its own coding and organisation of care. It would need to be validated on local data before any use elsewhere: in France, for example, on French data.

What does a concordance index of 0.80 mean?

Take at random one patient who will receive the diagnosis and one who will not: the model assigns the first a higher risk in about 80% of cases.

Why predict psychosis and bipolar disorder together?

Because the two disorders share some of their early signs and clinical features.

Does the model use laboratory tests or imaging?

No. It relies only on information already in the clinical record. That is its practical appeal, and it is also what makes it dependent on the quality of that record.

Will a patient classed as high risk necessarily develop a disorder?

No. The six-year cumulative incidence of either disorder is 8.27% in this cohort.

Do ketamine and esketamine improve quality of life in depression?

This review does not measure quality of life: it covers functional impairment and work productivity.

Why did the authors not run a meta-analysis?

They cite the small number of eligible studies and their heterogeneity in design and in the reporting of results. They also note that the instruments used to measure functioning are not standardised.

Can esketamine be prescribed in office-based practice?

That depends on the local framework, which treats marketing authorisation, the conditions of prescribing and dispensing, and reimbursement as distinct questions. In France, for example, it cannot.

Do one author’s competing interests invalidate the review?

No, but they matter when reading it. Here, the absence of a meta-analysis leaves room for interpretation in the synthesis, and that is precisely where a competing interest can weigh.

What kind of exercise should I suggest to a patient who sleeps poorly?

In this network meta-analysis, combined exercise (for example aerobic and resistance training), high intensity, four sessions a week, sessions of 30 minutes or less and a programme of nine to ten weeks are the…

What does SUCRA mean?

It is an index, expressed as a percentage, that summarises an option’s position across all possible ranks in the network of trials: the higher it is, the better the option ranks.

Do these findings apply to patients under psychiatric care?

With caution. The trials include participants aged 13 to 85 from very diverse populations, and the inclusion criteria did not require disturbed sleep at entry.

Why is the absence of GRADE a limitation?

Because GRADE is the tool that indicates how far each estimate can be trusted, taking into account bias, imprecision and heterogeneity. Without it, there is no knowing whether confidence is high or very low.

Can perospirone be prescribed?

That depends on the marketing authorisations of the country where you practise. In France, for example, no medicinal product containing perospirone is listed in the public medicines database, consulted on 2 October…

Does the trial show that perospirone works as an add-on treatment?

Not in a confirmatory way. Remission at eight weeks is more frequent at the nominal threshold, but no longer so in the sensitivity analyses; the difference in response is not significant, and no correction was made for…

Should an antidepressant be augmented as early as four weeks?

The trial suggests faster benefit when augmenting at that point, on secondary outcomes. It does not compare early with late augmentation, which would be the real question.

Why is a 60% placebo response a problem?

Because it leaves little margin to show a difference. A high placebo response reduces the power of the trial and makes a negative result hard to interpret.

Which antipsychotic should be chosen for irritability in autistic children?

The review does not conclude in favour of one drug. Risperidone and aripiprazole may reduce irritability by roughly 6 to 8 points out of 45, with low certainty; the gap between them is 1.63 points (95% CI 0.34 to 2.93)…

What does a SUCRA of 99.6% mean?

It is the relative probability of being the best treatment in the network, not a measure of advantage. It has to be read alongside the score difference, here 1.63 points on a 45-point scale.

Is lurasidone effective for irritability in autism?

In this review it probably makes little or no difference compared with placebo (-1.30; 95% CI -5.46 to 2.86), with moderate certainty.

Are these drugs safe?

The data do not allow a conclusion of safety. Weight gain (123 versus 51 per 1,000) and extrapyramidal effects (121 versus 51 per 1,000) are more frequent than on placebo in the trials, but the authors judge these…

Do these results apply to autistic adults?

The review does not allow a conclusion for adults: a single trial, 31 participants, medium-term follow-up, and no network analysis possible.

Do antihypertensives improve negative symptoms in schizophrenia?

Not in a demonstrated way. The meta-analysis finds a modest average improvement on the negative PANSS, but it rests on very different molecules, with a larger effect for intravenous nitroprusside, and the prediction…

Why does the prediction interval change how the result reads?

The confidence interval locates the average effect of the included studies. The prediction interval gives the range in which the effect of a new study would fall.

Can sodium nitroprusside be used in practice?

No established place. In the trials, it is given at 0.5 µg/kg/min for 4 hours intravenously, as a single or repeated infusion, in inpatients or outpatients; this route has not been evaluated in routine practice.

Do spironolactone, telmisartan and clonidine have a place?

No established place. Telmisartan and clonidine are each represented by a single trial, and diuretics have a non-significant effect on the negative PANSS in the review; their signal on the total PANSS does not survive…

Should we speak of a class effect?

No. The molecules pooled have distinct mechanisms, the hypothesis of a common mechanism (cerebral perfusion) remains speculative according to the authors, and the review does not allow one to speak of a class effect.

Do omega-3 fatty acids protect against Alzheimer's disease?

This study cannot say. It notes that 20 of the 57 lipid species associated with less severe biomarkers at baseline contain DHA, but these are cross-sectional associations, not a supplementation trial.

Can these lipids be measured in practice?

The study does not assess this use. Assay of 749 species by chromatography coupled with mass spectrometry is not available in routine care.

What does the acronym ATN stand for?

It groups three families of biomarkers: amyloid (A), tau (T) and neurodegeneration (N).

Have these results been confirmed in another cohort?

No. The authors point out the lack of large independent data for replication and call for it to be reproduced in other cohorts with lipidomics and longitudinal biomarkers.

Is pramipexole cost-effective in treatment-resistant depression?

In the UK health system, yes in the main analysis: £5,069 per QALY at 12 weeks and £9,007 at 48 weeks, below the usual thresholds.

What is a QALY?

It is a quality-adjusted life year: a year in full health counts as 1, a year with impaired health counts as less. The cost per QALY is used to compare very different treatments.

Can this result be applied in France?

Not directly. The tariffs and thresholds are British, and pramipexole has no authorisation for depression in France.

Why is the 48-week result considered fragile?

Because 22% of data are missing (partly because participants recruited after September 2023 had shorter follow-up), because treatment discontinuation differs between arms (20% versus 5%), and because the analysis…

Does the lack of reimbursement mean the treatment is ineffective?

No. Authorisation, marketing and reimbursement answer different questions, and a coverage decision does not say that a treatment is ineffective.

Is CBT effective for stimulant use disorders?

It may increase short-term abstinence, according to the authors: odds ratio 2.88 (95% CI 1.08 to 7.70), with substantial heterogeneity and low certainty. The longer-term effect is not established.

What does an I² of 75.62% mean?

That a large share of the variability between trial results is not explained by chance.

Is there a medication for these disorders?

According to the authors, there is no approved pharmacotherapy. Contingency management is the best-supported psychosocial approach, but it is difficult to implement in many settings.

Is CBT alone better than another psychotherapy?

The review cannot say: the comparator is minimal treatment, and trials comparing CBT with other psychotherapies were excluded.

Do these results apply to all stimulants?

Not in a demonstrated way. The effect is significant for methamphetamine or amphetamine (OR 9.14; 1.69 to 49.35) but not for cocaine (OR 1.26; 0.42 to 3.72); the difference is at the borderline of significance (p =…

Does this meta-analysis show that OCD worsens bipolar disorder?

No. Twenty-two of the twenty-six studies are cross-sectional, meaning the comorbidity and the outcome are measured at the same time. The work establishes an association, it does not fix a direction for the relationship.

Is the odds ratio of 1.85 for suicide attempts usable in consultation?

It is usable as a signal of vigilance, not as an individual risk calculation, and it is less solid than its presentation suggests.

Why isn’t the odds ratio of 9.42 for chronic episodes emphasized?

Because it rests on two studies, fifty patients in each group, and its confidence interval runs from 2.23 to 39.89.

What should we make of the authors’ declared use of ChatGPT?

The authors state they used it to improve the readability and language of the manuscript, then reviewed and corrected the content, and take full responsibility for the publication.

Should OCD be treated in a stabilized bipolar patient?

This publication does not settle the question: it evaluated no treatment and could not even control its results for treatments received, for lack of data.

Can I tell a patient that exercise cuts their dementia risk by 39%?

No, for three reasons. The 39% figure is not published: it is calculated from the hazard ratio of 0.61. That ratio describes a risk difference between two fitness groups, not the effect of an intervention.

Is the dementia finding stronger than the depression finding?

Yes, and the authors say so explicitly. The GRADE rating places all-cause dementia at moderate certainty for the high-versus-low fitness comparison, and depression at very low certainty.

Did the analysis exclude cases occurring in the first years of follow-up?

No, at least not in what the main text reports. The three published sensitivity analyses remove each study one at a time, separate hazard ratios from odds ratios, and apply a Hedges’ g correction.

What are the anxiety disorder results worth?

The pooled estimate is 0.90, with a 95% confidence interval of 0.75 to 1.09, across two studies, 36,687 participants, and 1,009 incident cases, with a heterogeneity of 56.9% and very low certainty of evidence.

Does the result hold in women and across age?

For depression, yes, as far as the subgroup analyses allow: 0.51 (95% CI 0.39 to 0.66) in women and 0.55 (95% CI 0.51 to 0.60) in men.

Should I measure my patients’ cardiorespiratory fitness?

That is neither realistic nor useful in outpatient psychiatry, and the study does not propose it. The objective measurement here is a research tool, chosen for the validity of the exposure.

Who funded this work?

Public bodies only, according to the printed declaration: Uruguay’s national research and innovation agency, the University of Castilla-La Mancha with co-financing from the European Social Fund, the Spanish national…

Does varenicline become a treatment for alcohol use disorder?

No. This is a phase 2 trial, conducted in a single country, over thirteen weeks, in a selected population.

So the varenicline and bupropion combination has no value at all?

The precise formulation is more cautious. The trial did not demonstrate superiority of the combination over varenicline alone for reducing consumption, with p values of 0.97 and 0.76.

Is bupropion ineffective in alcohol use disorder?

That is not what the trial shows, and the same caution applies as to the previous question.

How good is blood phosphatidylethanol as an outcome measure?

It contributes something real: an objective measure of alcohol exposure over the preceding weeks, one that does not depend on what the patient reports, which is a notable advance in a field where endpoints are almost…

Do the authors’ conflicts of interest invalidate the trial?

No, and it is important to stay factual. Five of eleven authors are co-owners of the company Sobrera Pharma AB, including the first author and the last author, who are its founders. These ties are disclosed.

Should this be read as recommending the lowest starting dose?

Not on the basis of this work. The authors do recommend favoring 56 mg before escalating to 84 mg, but their analysis does not support this recommendation: it compares two dose classes on tolerability, the high class…

Is nausea absent at low dose?

No. The result reported at low dose is non-significant, with a point estimate pointing toward an increase, relative risk 1.69, interval 0.81 to 3.55.

Is the intravenous route better or worse tolerated than the nasal route?

This work cannot answer that. The publication itself is inconsistent about how many trials are concerned: its characteristics table lists three by intravenous route, its limitations section mentions only one.

What should be made of the difference between international and Chinese trials?

That the differences run in both directions. Nausea, somnolence, and headache are reported more often in international trials; elevated blood pressure is more frequent in Chinese trials, relative risk 6.67 versus 2.67.

Do these results say anything about long-term tolerability?

No. Follow-up durations range from 4 hours to 24 weeks and most trials cover the acute phase; long-term data are not reported in this work.

Can a patient be told that their anxiety disorder shortens life expectancy?

No. This data does not establish that, and the observational design would not allow it even with more robust figures.

Does an I² of 99% make the meta-analysis unusable?

It does not cancel it, it changes what can be drawn from it. Dozens of studies converging on an excess in suicide mortality remains an argument for direction, especially since the confidence interval sits entirely above…

If the excess mortality disappears after matching on comorbidities, is anxiety alone harmless?

That conclusion would be a misreading. A non-significant difference is not proof of no difference, and these matched analyses rest on few studies, with comorbidities that vary widely from one study to the next.

Does this call for particular somatic surveillance in anxious patients?

The synthesis does report an excess in natural-cause mortality (RR 1.25) and in cardiovascular mortality (RR 1.26), and the authors draw from this an explicit call not to neglect general somatic care in these patients.

Does the finding hold equally for post-traumatic stress disorder and for generalized anxiety disorder?

The population includes stress-related disorders, and these two categories are the only ones showing a significant excess in all-cause mortality against the general population.

What does this work change for patient management?

Nothing on the therapeutic side: no intervention is evaluated, and nothing here supports the claim that any treatment would change this mortality.

Can we conclude that esketamine is superior to racemic ketamine?

No. The study is observational, product allocation is not random, assessment is open-label, and power on the secondary outcomes is insufficient.

Is non-inferiority on the MADRS decrease firmly established, then?

It is met according to the criterion the authors had set: less than a three-point difference between groups, with power of at least 0.97 to detect a small effect.

What exactly does the target trial emulation framework mean?

It is a method that consists of first defining the randomized trial one would have wanted to run, then reconstructing that structure from observational data, while explicitly checking four assumptions: exchangeability…

Do the cost differences transpose elsewhere?

The amounts cited in the publication come from a 2019 US source, not from Swiss data or from any other national data. They depend on insurance coverage, health system contracts, and wholesale prices.

Why does blood pressure tolerability differ between the two products?

The study reports a larger mean systolic and diastolic elevation under racemic ketamine, without establishing a mechanism.

Is mindfulness better than cognitive behavioral therapy?

For anxiety, it ranks higher. A better rank means a higher probability of being among the most effective modalities, which is not the same thing as demonstrated superiority between two approaches.

Do these results hold for children?

The authors ran prespecified age analyses on all three outcomes. For anxiety, the effect is stronger in adults than in children and adolescents, but it remains significant in the latter.

What about autistic people with substantial support needs?

They are very sparsely represented, and the authors themselves state this as the study's first limitation. Nothing in these data says these interventions work for them, nor that they do not.

Was GRADE applied, and what does it show?

Yes, comparison by comparison. Of the thirty-two comparisons graded, none reaches the high level: eight are moderate, twenty-one are low, and three are very low.

Can these interventions replace medication?

The network contains no medication arm: protocols combining a drug or a neuromodulation technique were excluded from the outset.

Does this study prove that adherence reduces mortality?

No. It shows a strong, graded association. The observational design cannot rule out that low coverage is largely a marker of a more compromised clinical and social situation, or that it is sometimes a consequence of a…

Is the number needed to treat usable in consultation?

Only with real caution. It is derived from survival differences projected at five and eight years, while median follow-up is 17.3 months, and it assumes a causal relationship the study does not establish.

Which patients do these figures apply to?

Adults covered by commercial insurance or Medicare Advantage in the United States, mean age 55.3 years, SD 20.5, who are starting or restarting an antipsychotic after 12 months with no dispensing at all.

Do the results hold up when the assumptions change?

Yes, in the same direction. Five sensitivity analyses, excluding the pandemic period, an alternative coverage calculation, three different cut-points for the adherence categories, adjustment for initial antipsychotic…

Who funded this study?

Johnson & Johnson Innovative Medicine. Five of the six authors are Johnson & Johnson employees, and are reported to have taken part in the design, analysis, interpretation, writing, and decision to submit.

Can esketamine be prescribed alone, without an oral antidepressant?

Current European marketing authorization requires administration together with an oral antidepressant, but this trial was conducted entirely in the United States and does not itself alter any regulatory framework.

Does this trial mean the oral antidepressant serves no purpose?

No. The trial compares esketamine alone against placebo, never esketamine alone against esketamine combined with an oral antidepressant.

Is a 6.8-point difference on the MADRS clinically meaningful?

It corresponds to a moderate effect size, a Cohen’s d of 0.63, and it exceeds the two-point threshold the authors treat as clinically significant, drawing on the regulatory literature.

Should 84 mg be preferred over 56 mg?

The trial was not built to compare the two doses against each other, and no formal test opposes them.

Did the blinding hold?

Imperfectly, and the trial had the honesty to measure it. Asked on day 28, 71.1% of patients on 56 mg and 78.3% of patients on 84 mg were strongly convinced they had received esketamine, against 46.9% of placebo…

What should be expected before this changes practice?

Replication by a team with no financial ties to the manufacturer, and a controlled follow-up period well beyond four weeks. The two conditions are independent, and both are necessary.

Can lamotrigine be used to treat a bipolar depressive episode that is currently underway?

An effect exists, and it is small (SMD 0.155, lower bound 0.005). It does not place the drug among the fast-acting options, and the slow titration required by its safety profile makes it poorly suited to an acute…

Does this meta-analysis prove that lamotrigine is ineffective in unipolar depression?

No, and the nuance matters. It shows that, after including three unpublished trials, no efficacy is demonstrated, neither alone (SMD 0.10, 95% CI −0.20 to 0.41) nor as an add-on (RR 0.95, 95% CI 0.73 to 1.23).

Does lamotrigine outperform lithium?

No superiority is demonstrated: in maintenance, RR 0.82 (95% CI 0.63 to 1.06) on emergence of depressive symptoms and RR 0.90 (95% CI 0.68 to 1.18) on duration free of symptoms, in 350 patients versus 242.

Why do the unpublished trials change anything?

Because negative trials are published less often, and later, than positive ones. Here, three unpublished trials in unipolar depression weigh on the result.

Should the journal this appeared in factor into how it is read?

It is worth knowing, without turning it into an indictment. The work is published in an open-access, author-pays journal.

Can pramipexole be prescribed for depression in France?

The product’s summary of characteristics, consulted on the ANSM public medicines database on August 10, 2026, lists only two indications: idiopathic Parkinson’s disease in adults and moderate to severe idiopathic…

Was this trial a crossover design?

No. Parallel groups, 1:1 allocation, nine weeks, with no sequence crossover, in both the published article and the 2023 protocol.

Does the functional MRI prove the mechanism?

No, even though the result is quantified. The imaging, performed at 7 teslas in 48 participants, shows a significant between-group difference (p = 0.030; Hedges’ g 0.64), with reward-related ventral striatal activation…

Is a four-point change on the SHAPS a lot?

It is roughly 10% of the baseline score. The SHAPS comprises 14 items rated 1 to 4, a range of 14 to 56, and patients entered the trial with mean scores of 41.5 and 39.5.

Were impulse control disorders observed in this trial?

Yes, and they were measured with a dedicated instrument, not only collected spontaneously.

Did mood switches occur?

Yes. Two patients in the pramipexole group developed mild manic symptoms: decreased need for sleep, increased energy, flight of ideas. The clinical point is that both were dysthymic, not bipolar.

Was the trial funded by a pharmaceutical company, and do the authors have conflicts of interest?

Funding came from the Swedish Research Council, ALF government health-care research grants, Region Skåne, and several Swedish foundations, and the article states that funders had no role in the trial’s design or…

Does the 60.1% poor-outcome figure apply to an adolescent seen today?

Not directly. It comes from a single meta-analysis of cohorts followed for a mean of 14.4 years, under earlier models of care, and the definition of poor outcome used is not given in the version reviewed.

Should clozapine be offered earlier than in adult practice?

The authors recommend considering it after resistance to two non-clozapine antipsychotics, without specifying a timeline particular to adolescents.

Can the tolerability ranking between molecules be trusted?

With reservation. The work recalculates no effect of its own, the rankings come from meta-analyses of uneven quality, ranging from 4 to 16 of 16, and five of the fourteen authors report ties to manufacturers.

Do the more pronounced cognitive deficits mean early-onset psychosis damages the brain more?

This cannot be demonstrated here. Early onset is associated with more severe forms of illness, and the observed association does not allow the two to be separated.

What about molecules discussed here that are not available where you practice?

Check local status before drawing on any of these figures. Molindone is no longer produced, asenapine has no European authorization in schizophrenia or in adolescents, and lurasidone's actual availability should be…

Does the absence of a result on inflammation mean there is nothing to look for there?

No. The negative result rests on 4 studies and 261 subjects, with high heterogeneity and planned complementary analyses that were abandoned for lack of data. This is insufficient power, not a refutation.

Why not pool the trials and the cohorts to gain power?

Because they do not measure the same thing. The trials estimate a standardized mean difference on consumption, the cohorts a hazard ratio on recorded events.

Do the negative trials prove that these molecules do not work on alcohol?

No. Three short trials totaling 430 patients lack the power to rule out a moderate effect.

The hazard ratio of 0.64 looks very precise, why not trust it?

Because the precision of an estimate and its validity are two different things. A narrow confidence interval means the association is measured accurately.

Is semaglutide more effective than the others?

Nothing in this article supports that claim. The signal referenced comes from subgroup analyses where each molecule is represented by a single study in the randomized arm, and by a single study for three of the four…

What would settle the question?

Randomized trials of sufficient size, with a validated consumption endpoint, a duration beyond a few months, and a population that actually includes patients with alcohol use disorder.

A parent asks me if it works. What should I tell them?

That the available studies are too few, too small, and too different from one another to draw a conclusion, and that this holds for both the daily and the accelerated forms.

Is it a problem that all the trials come from the same country?

It is a limit on generalizability, not a judgment on their quality. Associated care practices, concomitant treatments, and recruitment methods differ, which makes extrapolating to adolescents treated outside China…

Is the technique dangerous in adolescents?

No serious event is reported in what has been published, but only one trial in five organized the recording of adverse events, which rules out any reassuring conclusion.

And what about the finding on suicidal ideation?

It comes from a single trial, under the daily protocol and single-blind, and it has not been replicated.

Why didn’t the authors perform a meta-analysis?

The authors state that meta-analysis was not feasible given the amount of data available.

How long should sessions continue, and at what pace?

This synthesis does not answer that question. Its primary outcome is fixed at six months, and it does not compare different durations or schedules against one another.

Is the benefit the same in patients with bipolar disorder?

This synthesis cannot say. Three of the four trials included only unipolar forms, and no analysis by polarity was conducted, the number of trials being too small to allow subgroups.

Should medication treatment be maintained in parallel?

Yes, that is the very condition of inclusion. Maintenance sessions were evaluated in combination, never alone, and both arms received active continuation pharmacotherapy.

Why are existing guidelines more cautious?

Because they rely on a set of trials selected under different criteria. The 2022 UK meta-analysis retained only two trials, one of them using low-dose right unilateral placement, and excluded two others for reasons…

What should be taken from the prediction interval?

That one should be cautious about quoting a figure to the patient. The prediction interval estimates what a subsequent trial would show, and it includes the possibility that no significant benefit would be found.

Is this trial positive or negative?

Negative on its primary outcome, and the authors say so themselves. The secondary findings are small, and some of them are exploratory.

Why do the effect sizes in the abstract differ from those in the text?

Because they measure two different things. An interaction effect size measures a difference in trajectory between the two arms over time.

Was the active comparator a sound choice?

Methodologically, yes: it controls for attention, time, and format. The cost is that nothing is known about how the intervention would compare with no intervention at all, and the authors acknowledge this among their…

Does this transfer to students outside China?

The protocol does, it assumes nothing specific to the setting. The context does not: mandatory boarding, a single high-stakes exam, a distinct school culture.

Is magnetic stimulation safer than esketamine?

This work does not allow that conclusion. The observed gap on somatic events is confounded with a gap in monitoring intensity, a caveat the authors state in their limitations, and it narrows over time for injuries and…

What is a target trial emulation actually worth?

It is a rigorous framework that requires writing the protocol before analyzing, fixing time zero and synchronizing eligibility, assignment and the start of follow-up, which removes several classic errors of…

Should the suicidal signal between 30 and 90 days be taken seriously?

With caution, which is also the authors’ own position. It is the only significant window on this outcome, within a set of uncorrected multiple comparisons, with an interval lower bound of 1.031.

Can a first-line preference be drawn from this?

No. The question remains open, and the scarcity of direct comparisons between these two treatments is the real takeaway of this publication.

Can I conclude that adding brexpiprazole helps patients who barely respond at all?

No, not from this work alone. It shows that a gap exists in a pooled dataset, about two and a half MADRS points on a scale that runs to 60, with an effect size of 0.41.

Why does the effect look larger in patients who were doing worst at baseline?

The analysis cannot answer that. The authors point to the higher baseline score in this subgroup, which mechanically leaves more room for improvement.

Does the weaker result in partial responders mean the strategy doesn’t work in this group?

No, and the result is not negative either: the difference reaches the conventional threshold, on both the MADRS and the CGI-S, but narrowly and without correction for multiple comparisons.

Is industry funding enough to dismiss these results?

No, and saying so would be as careless as ignoring it. The data come from randomized, double-blind trials, and the source of funding does not make a number false.

What do we know about tolerability in this analysis?

It is reported, and it deserves to be read before the efficacy findings. At least one adverse event occurred in 59.8% of patients under brexpiprazole versus 47.8% under placebo among minimal responders, 54.8% versus…

Does this trial show that psilocybin treats post-traumatic stress disorder?

No, and it was not designed to. Its primary endpoint is safety. The reductions on the CAPS-5 and PCL-5 are secondary endpoints observed in a single arm, with no placebo and no blinding.

Isn't a Cohen's d of 2.13 huge?

Numerically, yes. But an effect size calculated on a before-after change within a single group and an effect size calculated between two randomised arms do not measure the same thing and cannot be compared.

Is psilocybin legal?

That depends on the jurisdiction: psilocybin is a controlled substance in most countries, and its precise legal status varies from one to another.

Can we call this safe, since there was no serious adverse event?

No. Twenty-two exposed people is too few to detect a rare event, and zero cases observed among 22 remains compatible, by the rule of three, with a true frequency of up to roughly 14%.

Is there a risk specific to trauma?

Yes, and it is specific to this indication. The psychedelic experience can bring traumatic material back to the foreground, as documented by the qualitative study conducted on the same cohort.

What would it take to draw any conclusion about efficacy?

A randomised trial against a comparator, with blinded raters, an adequate sample size, an identical psychological support package in both arms, and follow-up beyond three months.

A patient asks me if a single session can be enough for a year. What should I answer?

That this is exactly the question this trial tried to answer, with the first comparative follow-up maintained for twelve months, and that the answer obtained on the reference measure is negative.

If everyone guesses their allocation, does the trial still have value?

Yes, but not the value usually credited to it. It loses its ability to quantify an effect on subjective endpoints.

Isn't remission in one patient out of two at six weeks a major result?

It is a spectacular and fragile result. It rests on 17 patients per arm, its confidence interval spans nearly two orders of magnitude, it is not adjusted for baseline value even though the psilocybin arm started three…

The placebo arm responded very little. Doesn't that strengthen the case for the drug's effect?

That is the interpretation the authors propose, and it is not the only one possible.

Can I refer a patient to a protocol abroad?

This question goes beyond what this trial can answer and falls under regulatory and ethical frameworks rather than the data.

Does a p-value of 0.087 with an effect size of 0.72 mean pramipexole almost works?

It means the trial did not have the power to answer the question. With thirty-six patients analyzed instead of the 290 randomized patients targeted, the confidence interval is too wide to rule out either no effect or a…

Why not rely on the 46% response rate at study exit?

Because it covers twenty-nine patients, with one cell at zero, no multiplicity correction, an exit criterion redefined partway through the trial, and follow-up durations ranging from sixteen to forty-eight weeks, and…

Is the 44% figure for hypomanic or manic events reliable?

It rests on eighteen exposed patients, which makes the estimate imprecise, and it reflects reported adverse events, not manic switches confirmed by a standardized assessment.

Should this trial be repeated?

The authors publish a revised power calculation that sets the definitive trial at 34 patients per arm, that is 68 randomized and 95 recruited beforehand, a target far more attainable than the original one.

Does this study show that group EMDR works for forced migrants?

No. It shows that a group EMDR program could be delivered to 71 exiled people with a low dropout rate.

The drop in complex PTSD from 60.9% to 15.2% still looks impressive.

The magnitude is real, the interpretation is not, and reading it in isolation is misleading. These percentages cover 46 patients, that is, 28 then 7 people.

Is the group format really less dependent on language?

This is the authors' working hypothesis, based on the use of written worksheets and self-administered bilateral stimulation.

Does the group format actually save time?

Not much. The authors did the calculation: two therapists for a 2.5-hour group of six participants on average represent a 17% time gain compared with one-hour individual sessions, and this gain shrinks further once a…

Are all the announced outcomes reported?

Yes, the six primary outcomes appear in the results table with their sample sizes, medians, means, confidence intervals, p-values and effect sizes.

Is this the first French study on this format?

That is not what the authors claim. They present their work as the first formal evaluation of this particular adaptation of the GTEP protocol, a narrower and more defensible claim.

Does heat increase suicide risk?

This study cannot answer that at the individual level. It observes that hotter summer months are associated with higher suicide rates across US counties, between 1980 and 2004, among 15 to 24 year-olds.

Why does a study published in 2026 stop at 2004?

The authors explain this by data availability. At the start, 1980 is the year the number of weather stations feeding the climate database used increased by half, which led the research community to recommend not going…

How many additional deaths does this represent?

The authors offer a projection, which should be read as such. Applying the summer baseline rate for 15 to 24 year-olds, 0.955 per 100,000, to the 43 million Americans in that age group, they estimate that one additional…

Should suicide-risk screening be stepped up during heatwaves?

This study does not support such a recommendation. It concerns a different country, a different period, and a different level of analysis.

Is the mechanism known?

No, and the study measures none. The leads the authors raise in their discussion, brain connectivity, impaired sleep, reduced heat acclimatization in young people, changes in summer social activity, rest on other…

Do two-thirds of patients with schizophrenia have sarcopenia?

In this Turkish sample of 198 patients, 66.6% met EWGSOP2 criteria, most at the probable stage, which rests on grip strength alone.

Are antipsychotics to blame?

The study does not answer this question. Antipsychotic class, use of a long-acting injectable formulation and adherence did not differ between patients with and without sarcopenia, and mean treatment duration, close to…

Should sarcopenia screening be implemented?

The authors recommend systematic screening in psychiatry and propose grip strength measurement as a simple tool.

Does oxidative stress explain the muscle loss?

The data show positive correlations between serum antioxidant capacity and muscle parameters, in the range of r = 0.21 to 0.29.

Can esketamine be offered to a patient with treatment-resistant OCD?

Not on the basis of this study. An eight-case series with no control group does not establish an indication; at best it justifies a controlled trial.

Isn’t an effect size of 1.51 considerable?

The figure is high, but it is calculated on eight patients selected for their extreme scores, with no comparator.

Is the gap between depressive and obsessive response an established finding?

No. It is described from mean trajectories in eight patients, with no statistical test of a difference in kinetics reported. It is an interesting hypothesis, not a result.

Does the absence of treatment discontinuation mean the drug is well tolerated long term?

No. Across eight patients followed for twelve weeks, only frequent, early effects can come to light. Nothing here can be said about rare effects or about tolerability beyond three months.

What should clinicians outside a specialized center take from this?

Mainly the characterization of this population, severe on both dimensions, and the idea that a longer assessment window may be needed on the obsessive-compulsive dimension.

Why did the authors not perform a meta-analysis?

They give two reasons. The first, stated in the methods, is that no new randomized data had been identified since the systematic review by Youssef and McCall.

Is lithium the best option?

It is the option with the most consistent evidence, which is not the same thing. Much of that evidence is observational, and no direct comparison with the other strategies is pooled here.

What about a patient with bipolar disorder?

This review excludes them, on the grounds that the course, pathophysiology and prevention recommendations differ from those of unipolar depression.

Can psychotherapy be offered as a follow-on treatment?

The authors classify it as an emerging lead, based on a single randomized trial of 60 responders and a prospective cohort of 8 patients. That is not much.

What does the absence of studies on ketamine mean here?

Only that no study meeting the inclusion criteria was found for this specific indication. Trials are registered and not yet published, which the authors note.

Is this test usable in consultation?

No. It is a research task lasting about thirty minutes, not validated as a clinical tool, and its individual predictive value has not been established.

Is a correlation of −0.58 strong?

It is considered moderate to strong in absolute value, but here it rests on twenty-three subjects and no confidence interval is reported.

Does this mean stimulation acts on reward circuits?

That is the authors’ hypothesis, and it is consistent with the result. The study includes no brain measurement that would establish this directly.

Do non-responders have a collapsed pursuit of reward?

The source does not show this. It reports that gains in preferred rewards increase across weeks in the 18 patients whose anhedonia improves, and do not change in the 7 patients with no improvement.

Does the result hold if patients are simply asked what they prefer?

No. When the ranking of categories is based on the ratings patients give the videos rather than on their choices, the association with the decrease in anhedonia is no longer found.

Is mismatch negativity abnormal in depression?

In this study, no significant difference was detected compared with healthy controls (d = 0.11), and amplitude was not correlated with baseline symptom severity.

Why isn’t the correlation in the active arm enough?

Because a treatment-specific prediction requires the association to be stronger under active stimulation than under sham.

What should be taken from the negative results?

The first, the comparison with controls, is the most informative, without excluding a small difference.

Should we conclude that sexual obsessions are more frequent when bipolar disorder is also present?

Not as things stand. The observed difference is modest, it crosses the significance threshold only narrowly, it disappears when almost any of the included studies is removed, and it vanishes when the analysis is…

What does heterogeneity of 88.9% to 93.7% mean?

That nearly all of the variability observed between study results reflects real differences between those studies rather than sampling chance.

Does a significant asymmetry test prove publication bias?

It strongly suggests it, without proving it. Asymmetry can also reflect genuine heterogeneity or quality differences between small and large studies.

Why doesn’t overall severity differ?

The pooled estimate does not cross the significance threshold, which suggests that comorbidity might change the shape of the symptomatology rather than its intensity.

Does this evidence change patient management?

No. Nothing in this study concerns treatment, therapeutic response or outcome. Its contribution is descriptive, and it can guide the clinical interview, nothing more.

What is a surface under the cumulative ranking curve?

It is a statistic that summarizes, for each node in a network, the probability of occupying the best ranks.

Should yoga be recommended over running for sleep?

Not on the basis of this article. The two modalities are analyzed here in two separate networks, with no comparison between them, and no certainty assessment informs the rankings presented.

Does exercise actually help in addiction?

This publication cannot answer that question: it reports no effect estimate of exercise compared with usual care or a waiting list, and no tolerability data.

Why is the stated level of evidence high when the conclusion is cautious?

Because the Oxford level describes the type of study, here a meta-analysis of randomized trials, not the robustness of its results.

Was this trial positive or negative?

Positive on its primary endpoint, with a confidence interval that excludes no effect.

Does brexpiprazole cause less akathisia than aripiprazole?

This trial does not allow that claim. The aripiprazole arm is an active reference meant to verify that the assay detects an effect, not a formally tested comparator.

Should we conclude the drug is ineffective against negative symptoms?

No. The trial did not demonstrate an effect on this dimension, which is not the same as demonstrating there is none.

Does the high placebo response disqualify the trial?

No, it reduces the margin available for demonstration. A 17.4 point improvement under placebo sits, according to the authors, at the upper end of the range expected from prior trials in adolescents, and is a reminder…

Do the conflicts of interest call the results into question?

Seven of the nine authors are or were employees of Otsuka or H Lundbeck, the two funders, who took part in the design, data collection, analysis, interpretation, and writing.

Can brexpiprazole be prescribed off-label to an adolescent?

That depends on the regulatory status where you practise, which must be verified against official sources and cannot be deduced from this trial.

Should an impulsive child be steered toward judo and a child who forgets instructions toward jump rope?

That would go beyond what the design supports. Each activity category was compared only with its own control condition, in separate trials, never against each other in the same children, and no test of difference…

What duration and intensity should be recommended in practice?

The clearest effects appear beyond six weeks, with at least two sessions a week, at moderate-to-vigorous intensity. Treat this as an order of magnitude, since these parameters come from subgroup analyses.

Will a child who improves on the tests do better in class?

Not demonstrated here, and caution is warranted. Cognitive training interventions in ADHD have shown gains on the trained tasks without a corresponding improvement in symptoms rated blind.

Are these effects comparable to those of an ADHD medication?

This work does not settle the question, and the figures are not interchangeable: medication trials are judged on symptom scales, these trials on cognitive tests.

Are there children for whom sport should not be recommended?

Few, and for somatic rather than psychiatric reasons: known cardiac or respiratory disease, orthopedic issues, or a situation where repeated failure in a competitive activity risks harming self-esteem.

Should an antiviral be offered to a patient worried about their memory?

No. No randomised-trial data support this practice, and the authors of this study themselves write that confirmation through randomised trials is needed to provide definitive evidence.

Does this critical reading refute the herpes hypothesis of Alzheimer's disease?

No, and that would be a symmetrical error. A study that establishes nothing does not refute anything either. The hypothesis remains open, it simply calls for a different kind of evidence.

Why isn't a very large sample enough?

Because size corrects for chance, not for bias. An unmeasured confounder acts the same way on three hundred people and on three hundred thousand, it is simply estimated with greater precision.

Is the result consistent with findings from other countries?

The two earlier studies on antiviral exposure identifiable in this publication's bibliography range from a hazard ratio of 0.09 in Taiwan to 0.89 in Sweden.

What does an SMD of -0.31 mean for a patient?

About 1.9 points on the PANSS negative subscore, calculated using the within-group standard deviation of 6.0 points observed in these trials.

Why dismiss the SANS figure when it looks far more favorable?

Precisely because it is more favorable. A result with 91% heterogeneity can take almost any value depending on which trials are pooled. Citing it, even with a caveat, still puts it into circulation.

Is the 20 Hz subgroup enough to fix a protocol?

No. It is enough to guide a choice when the protocol is not already fixed, and even then with the caveat that, with no pre-registered protocol, nothing shows this subgroup was planned before the analysis.

Should rTMS be offered first-line for negative symptoms?

Nothing in this work suggests it. This is a treatment given as an adjunct to patients already receiving an antipsychotic, and it is within that framework that the effect was measured.

Is rivastigmine more effective than donepezil?

This work cannot say. Both figures come from separate analyses, the confidence interval for rivastigmine is wide, and its estimate depends heavily on one small trial with atypical data.

Should donepezil be favored, as the authors suggest?

Not on the basis of this review. Donepezil is the only molecule with a significant effect on functioning and a non-significant excess of adverse events, but these results come from separate analyses with no comparison…

Is an effect of −0.33 clinically useful?

It is a small effect in standard-deviation units. This review does not report how it translates into a benefit the patient can perceive.

Why does the absence of GRADE matter?

Because an estimate can be precise and still rest on low-quality trials. Without a certainty assessment, there is no way to know how much weight to give each figure.

What does this review say about tolerability?

It reports a significant excess of adverse events with galantamine (odds ratio 2.34, 95% CI 1.35 to 4.08) and a non-significant excess with donepezil (1.22, 95% CI 0.98 to 1.52), without specifying which events were…

Does this trial justify adding an azapirone upfront to an antidepressant in an older depressed patient?

No. The benefit on mood and anxiety does not last beyond the first few weeks, the trial is single-center and of modest size, and the molecule tested is not available in France.

Can tandospirone be replaced with buspirone?

This is a hypothesis based on shared membership in the same pharmacological class, not a conclusion of the study.

What does a benefit on somatization actually mean?

It refers to change on scales of somatic complaints, the PHQ-15 and the Chinese version of the Somatic Symptom Scale.

Was tolerability measured?

Yes. Adverse events were recorded continuously on a form given to each patient, using the TESS severity scale, and supplemented with laboratory tests, an electrocardiogram and an electroencephalogram.

Is measuring platelet receptors useful in practice?

Not today. It is an exploratory peripheral marker whose link to central neurotransmission remains a hypothesis. It has not been validated as a decision aid or as a monitoring criterion.

Does the absence of a difference at twelve weeks mean the combination adds nothing for mood?

No, and this distinction matters in both directions. This trial did not detect a difference on mood at twelve weeks, which is not the same as demonstrating that none exists: with 134 patients, a difference of small…

Does this meta-analysis validate EMDR as a treatment for addictions?

No. It documents an effect on craving and on emotional dimensions, and no demonstrated difference on the severity of the addictive disorder.

What does a g of 0.55 mean for a patient?

It is conventionally a moderate effect. But the clinical translation of an effect size depends on the scale used and on the comparison situation, and here the comparators range from no treatment to cognitive behavioral…

Why does craving decrease when addiction severity does not move?

Two explanations remain open. Either the effect genuinely acts on emotional load and urge without changing, at this point, consumption behavior.

Is the effect really better for alcohol than for tobacco?

A meta-regression reports a difference favoring alcohol, and the subgroup analysis points the same way, g = 0.75 [0.50, 1.00] against g = 0.38 [0.24, 0.53].

How many sessions should be planned?

The included protocols range from one to twelve sessions, of 50 to 90 minutes, once or twice a week.

Should substance use be stabilized before starting trauma work?

This work provides no solid answer to this question, which would require a direct comparison of care sequences.

Can it be said that the ketogenic diet works in treatment-resistant depression?

No, and the authors do not say so. Their own wording is that an antidepressant benefit is observed at six weeks but that "the clinical relevance is uncertain," the mean effect being modest and absent from the secondary…

Why place so much weight on the absence of blinding for a dietary question?

Because the primary outcome is a scale the patient fills in themselves. When the person rating their own mood knows they belong to the experimental arm of a trial testing a diet they have heard about, the effect of the…

Does the result in severe presentations justify targeting those patients?

Not yet. The subgroup analysis is stated as prespecified, and severity was one of the minimization factors, which makes it more credible than an improvised analysis.

What does the absence of a link between ketones and improvement mean?

Ketosis is supposed to be the mechanism of action. The post hoc analyses find no significant association between ketone concentration and PHQ-9 change, and the participants least in ketosis were those who improved the…

Is the ketogenic diet dangerous in a depressed patient?

This trial reports no serious adverse event related to the research procedures over six weeks, with an explicit target of weight stability and weekly dietetic oversight.

What should be said to a patient who read that a ketogenic diet cuts depression by 70%?

That the figure is real, that it comes from a single-arm study of 16 analyzed participants with no comparison group, and that the question it poses is not the one it appears to answer.

Can it be said that ketamine keeps its antisuicidal effect in patients with severe treatment resistance?

No, not on the basis of this work. The test designed to detect a difference did not reach significance, but the point estimate, 0.72, points in the same direction as the significant interactions, and its interval…

Why is mixing the comparators a problem?

Because the quantity measured is a difference between ketamine and its reference.

What changes if multiple testing is corrected for?

The threshold required for each comparison becomes stricter. Across the seven interaction terms, a Bonferroni correction would lower the threshold to 0.0071: apparent sadness, at p = 0.002, would remain significant…

Does a post hoc analysis have any value?

Yes, that of generating hypotheses. It loses the protection that preregistration provides against choosing analyses after the fact.

Are these results transferable to intranasal esketamine?

Nothing in this study allows that claim. Molecule, route of administration, treatment schedule and population all differ. The question deserves to be asked separately.

Does this trial show that artificial intelligence makes care worse?

No, and it does not show that it makes care better on this endpoint either. The adjusted odds ratio for treatment failure at 14 days is 0.77, with a 95% confidence interval of 0.55 to 1.08 and p = 0.13.

Is this the first trial of its kind?

The publication does not claim that, and neither does this analysis. The authors write that rigorous evidence in real-world, low-resource settings "remains limited," which is not the same as nonexistent.

Why review a Kenyan primary care study in a psychiatry journal?

For the method, not the clinical content. This is one of the few randomized trials to evaluate a generative-AI decision support tool within the real flow of care, with a patient-centered endpoint and independent blinded…

Is a treatment-failure composite a good endpoint?

It has the advantage of capturing several ways a consultation can fail, and the drawback of aggregating events of very unequal severity, from a repeat visit for persistent symptoms to death.

What would it take to settle this question for psychiatry?

A randomized trial conducted in real psychiatric consultations, with endpoints chosen in advance and meaningful to patients, a measure of actual tool use, and follow-up longer than fourteen days.

Do these results apply to France?

Not directly. Recreational cannabis is not legal there, and the market, supply and prevention policies differ. These data inform a debate, they do not predict what a reform would produce in another country.

So is legalization safe for vulnerable people?

This study cannot say. It observes that reported frequency of use rose less among them than in the rest of the population.

Did use rise among people with anxiety or depression?

Yes, and the point is often lost in summaries. Past 12-month use rises from the first year after legalization, adjusted odds ratio 1.33 (95% CI 1.15 to 1.53) for anxiety disorder and 1.47 (1.26 to 1.73) for depression…

What about bipolar disorder, post-traumatic stress disorder and schizophrenia?

No significant change from 2018 is found, on either measure of use. This result should be read for what it is: analyses that were performed and proved inconclusive, in the smallest samples of the study, with very wide…

Why does the twofold gap exist?

The study observes it, it does not explain it. Several hypotheses coexist in the literature, from self-medication of symptoms to shared risk factors.

Does the declared conflict of interest call the results into question?

It does not invalidate them. It is declared, funding is public, and the tie concerns expert work against the tobacco, vaping and cannabis industries, not on their behalf.

Does this study show that antibiotics work better than antipsychotics for negative symptoms?

No, and that reading is methodologically impossible. This is a pairwise meta-analysis: each intervention is compared with a non-active comparator, never with another intervention.

Is there an approved medication specifically for negative symptoms?

Not for negative symptoms in isolation, but an authorization can cover them by name. France gives a concrete example.

Why does the distinction between primary and secondary negative symptoms change everything?

Because it decides the treatment. Social withdrawal secondary to persecutory delusions, to antipsychotic-induced akinesia or to depression calls for optimizing the current treatment, not for an extra drug.

How much is the 0.457 threshold worth?

It is the most solid contribution of the work, provided it is not credited with a novelty it does not have: the method comes from the same group’s 2015 meta-analysis and is reapplied here to a corpus three times larger.

Why do immunomodulators get high certainty while physical activity gets very low certainty?

GRADE certainty depends on risk of bias, consistency across studies, precision and directness of the evidence.

What should we make of the absence of clozapine and electroconvulsive therapy?

They could not be analyzed for lack of enough trials against a non-active comparator, since these treatments are usually compared with active treatment.

Does this change anything in my practice?

No. The study looks at no clinical outcome, uses no individual-level data and proposes no marker. It belongs to translational research.

So is the adolescent brain organized differently?

That is the hypothesis the authors put forward, and it is plausible given what we know about cortical maturation.

What does a correlation of 0.65 between two brain maps mean?

That the regions where thickness differs most between patients and controls tend to be those occupying a particular position in the network of connections.

Why is the level of evidence field empty?

Because the Oxford levels of evidence scale is built for questions of diagnosis, prognosis or treatment. It does not apply to a correlational analysis of aggregate statistics.

Does this point to a therapeutic lead?

No. The associations with neurotransmitter maps are exploratory and rest on average data drawn from other samples. None has been tested, and none identifies a usable target.

Does this meta-analysis show that quetiapine and haloperidol are equivalent?

No. It shows that no difference was detected in 215 patients across three trials. That is a different piece of information.

Do these results apply to my 88-year-old patient in acute geriatrics, or to a patient in palliative care?

Nothing supports that. The mean age of participants is 57.25 years and the care setting is not described in the abstract.

Is it permitted to prescribe either drug in this indication?

Haloperidol has an indication covering the acute treatment of delirium after non-pharmacological treatments have failed, in both oral and injectable forms, in the United Kingdom according to the MHRA and in France…

Should an antipsychotic be prescribed for delirium?

Not as a first-line measure. Guidelines agree on etiology and environmental measures.

Is the mortality result, a risk ratio of 0.60, reassuring for quetiapine?

No, and it should not be read that way. The confidence interval runs from 0.29 to 1.27, that is, from a 71% reduction to a 27% increase. With 215 patients, the number of deaths is necessarily small.

What should be taken from the reported heterogeneity?

It is low on the primary outcome, 10%, which makes the severity estimate relatively consistent across trials. It is major for sleep, 77%, and for response rate, 85%.

Can physical activity replace medication in ADHD?

This study does not test that and cannot support the claim. Trials combining physical activity with medication or psychological treatment were in fact excluded.

Why does aerobic exercise alone not stand out?

No significant difference is detected versus usual care for attention, memory or executive functions. This may reflect a true absence of effect, a lack of power or an ill-suited measure, and the study cannot tell which.

Is exergaming really useful?

There is a signal for attention, memory and executive functions when all disorders are pooled, with very low to low certainty.

Is a standardized difference of 1.91 a large effect?

It would be considerable, given that a value of 0.8 is already classed as large under the convention the authors use.

Do these results apply to patients in France?

With reservations. Five trials were conducted in Europe, in Switzerland, Italy and the Netherlands, but none in France, and most trials come from Asia and the Middle East.

Should a targeted psychotherapy be offered to a patient who still hears voices on antipsychotic treatment?

This data supports the proposal without making it mandatory. The average benefit is small in magnitude and the certainty of evidence is judged low by the authors, but it is maintained at follow-up and acceptability is…

Is avatar therapy superior to cognitive behavioural therapy?

This work does not demonstrate it. It shows that the six-trial avatar subgroup is the only one to reach significance against its own controls, while the three-trial cognitive behavioural therapy subgroup does not (0.05…

Why was the 2020 Cochrane review negative on avatar?

It had three studies and 195 participants available, all at high risk of bias on at least one domain, with certainty levels mostly very low to low and short-term data only.

What does a standardised mean difference of −0.18 actually mean for a patient?

No direct translation is possible. This index expresses a gap between means relative to the dispersion of the measurements, which allows different scales to be pooled but forbids converting it into scale points or fewer…

Does the fact that the patient knows what they are receiving invalidate the study?

No, and the article provides the means to check this. In a psychotherapy trial, blinding the participant is impossible; what remains possible, and becomes decisive, is blinding the assessor.

Are these interventions available anywhere today?

The sources consulted do not allow a description of the French care offer specifically, and none of the twenty-three included trials was conducted in France.

Does this stimulation treat opioid use disorder?

No, and the trial was not designed to answer this question. It measures an immediate brain response after a single session. Neither use, nor relapse, nor treatment retention, nor mortality was assessed.

Was the primary endpoint negative?

No, and this is the main misreading to avoid. The primary endpoint prespecified in the registry was an imaging endpoint, the change in BOLD signal during a drug cue-exposure task, and it is met.

Did the blind hold?

The authors tested it, and tested it statistically, which is to their credit. Most participants in both groups believed they had received real stimulation: 24 in the sham arm and 25 in the active arm after the…

Why does craving fall in the sham group too?

Several mechanisms combine: expectation of an effect, regression to the mean after a high initial measurement, habituation to the repeated exposure task, and the residential care context.

Is this device available or reimbursed anywhere today?

A search carried out on 11 August 2026 on the French national health authority’s website found no opinion, evaluation, or reimbursed-procedure listing concerning transcranial alternating current stimulation in opioid…

What would it take for this to change practice?

A multiple-session trial, with a clinical primary endpoint rather than an imaging one, a credible sham arm, several months of follow-up, a population including women and outpatients, and stimulation assessed as an…

Does this mean fear disorders and generalised anxiety disorder are the same disorder?

No, and the authors do not say so. The sharing concerns the share of risk explained by common variants, and a partial specificity remains, visible in the correlations with other traits and in the genetic variance…

Does this result hold for all patients?

The data come exclusively from participants of European genetic ancestry, in the United Kingdom and Australia. No extrapolation to other ancestries is possible as things stand, for lack of analysis in those populations.

Why does the heritability look so low?

Because it is the share explained by the common variants studied alone, about 12% here, not the total heritability. Estimates from twin studies, 20% to 60% for anxiety disorders, do not measure the same thing.

Can a genetic test help in practice?

No. These results concern populations, not individuals. The single locus associated with fear disorders corresponds to an odds ratio of 1.07, with no individual predictive value at all.

Does this study prove that stimulants do not trigger mania?

No. It shows that no increase is detected among the 939 subjects hospitalised for mania during follow-up.

What is healthy-adherer bias, in concrete terms?

The periods during which a patient takes a treatment are often the periods when they attend follow-up, are doing better, and take care of their health.

Is lisdexamfetamine preferable?

The signal is more favourable for it in this study, 0.81 on psychiatric hospitalisations against 0.92 for methylphenidate.

What about atomoxetine?

It was analysed separately, in 2,470 patients, and does not reach the significance threshold on either psychiatric or substance-related hospitalisations.

Are these results applicable outside Sweden?

Conditions for prescribing stimulants to adults differ between countries, and in France, for instance, the context is more restrictive.

Does cannabidiol relieve anxiety?

Across the six trials pooled in this review, no significant effect is found on anxiety-related endpoints.

What about depression?

There is no randomised trial to analyse, across a search covering January 1980 to May 2025, the inclusion criterion being a cannabinoid given as the primary treatment for the disorder.

Do the favourable results concern cannabidiol alone?

None of them do, but the answer varies by indication. For cannabis withdrawal and tic severity, the full text shows that only the subgroup combining cannabidiol and delta-9-tetrahydrocannabinol reaches significance…

Is a product bought over the counter equivalent to what was tested?

Nothing supports that claim. The trials use products with controlled composition and a defined dose.

Is medical cannabis authorised in France for a psychiatric indication?

No, according to the official sources checked on 10 August 2026. The five clinical situations of the French scheme are refractory neuropathic pain, certain drug-resistant epilepsies, certain refractory symptoms in…

How should the figure of 7 be interpreted?

It is the number of people who need to be treated to observe one additional adverse event compared with the comparator, with a 95% confidence interval running from 5.4 to 10.8.

Does this review settle the question of the link between cannabis and psychosis?

No, that is not its object. It evaluates cannabinoids as a treatment. The question of cannabis as a risk factor belongs to a different literature, and a 2026 publication in the same journal finds credible evidence for a…

Could this device become a monitoring tool?

Nothing rules it out, but it would require, at minimum, independent replication, an evaluation of individual discriminative performance, correction for multiple comparisons, and a setup usable outside the laboratory.

Is the observed impairment a cause or a consequence?

The study cannot settle this. Prior undernutrition, illness severity, psychotropic medication present in 92% of patients, and a causal mechanism all remain equally compatible with the data.

Does the result hold for adolescents?

The included population ranges from 13 to 40 years old, with a mean age of 18.9, so it does include adolescents. But it is exclusively female, exclusively restrictive-type, and drawn from a single inpatient unit.

Why does the brain arm show nothing?

Gastric evoked potential amplitudes do not differ between groups. The authors do, however, report stronger correlations, in the anorexia nervosa group, between these potentials and the behavioural measures.

Does this justify referral to body-centred therapies?

It makes the hypothesis plausible, it does not demonstrate it. No intervention was tested in this work, and the effectiveness of an approach cannot be inferred from the existence of a mechanism.

If I treat the mother’s insomnia, will the child’s sleep improve?

Nothing in this work allows that claim. A cross-sectional correlation does not say what happens when one intervenes on one of the two terms.

Is a coefficient of 0.48 a lot?

It is a strong association for this type of literature, but it corresponds to roughly 23% shared variance, and its confidence interval runs from 0.24 to 0.66. At the scale of a given child, it predicts nothing useful.

Why is the link weaker when actigraphy is used?

First a clarification: the drop is not seen everywhere. It is marked for duration, efficiency and sleep continuity, and not significant for bedtime or wake-up time, where sensor and questionnaire agree.

Why is the coupling stronger with mothers than with fathers?

The result exists, but it is narrower than it appears and its interpretation is ambiguous.

Should we conclude that the family should be treated rather than the child?

This is a plausible conceptual orientation, not a demonstrated conclusion. This work establishes that sleep varies together, it does not establish that acting on one modifies the other, and it evaluates no family-based…

Should qigong be preferred over yoga or tai chi?

Not on the basis of this study. Qigong’s advantage in depression comes from a comparison between subgroups of different trials, not from trials that pit the practices directly against one another.

What does “high certainty” mean for anxiety?

That the authors consider it very unlikely that new trials against passive controls would change the result much. It says nothing about how these practices compare with another group activity.

Do these results generalise beyond the countries where the trials were run?

With caution. Twelve of the fifteen trials were conducted in China, including two in Hong Kong, in settings where these practices are culturally more familiar.

Does the effect last after the practice stops?

We don’t know. According to the authors, most of the included trials had no follow-up after the programmes ended, and the meta-analysis does not examine whether the effect is maintained.

Should quetiapine now be preferred over lithium?

Not on this basis alone. One of the two co-primary outcomes was met, the other was not.

Why was the trial not blinded?

Because the trial is pragmatic: the authors chose an open-label design to reflect real-world practice as closely as possible.

What should be taken from the discontinuation rate?

That it is high in both arms, and it may be the single most directly usable result of the trial. Adverse effects and an insufficient clinical response are the two main reasons behind it.

Does the cost-effectiveness result apply outside the NHS?

Not directly. Drug prices, monitoring arrangements, hospitalisation costs and willingness-to-pay thresholds all differ between healthcare systems. The method is informative, the figure itself is not transferable.

Can buprenorphine be prescribed for suicidal ideation today?

No. The use is off-label for this indication and rests on a single small trial. This is not a practice recommendation.

Is this strategy usable in outpatient private practice?

Not as it stands, since the protocol begins with a ketamine infusion, unavailable outside a specialized setting. The underlying reasoning, however, applies everywhere.

Why does suicidal ideation improve without depression changing?

This is the question the study raises without resolving it. Suicidality and mood may rest on partly distinct circuits, but this finding concerns a nonsignificant secondary endpoint in a sample of 45 patients, with no…

Were the patients treatment-resistant?

No. The published inclusion criteria are a major depressive episode and a score of at least 6 on the Scale for Suicide Ideation. Treatment resistance is not among them, contrary to what has sometimes been reported.

Should this be called a breakthrough?

No, and framing it that way would do the topic a disservice. It is an elegant proof of concept, in an area where usable tools are still scarce.

Does a hazard ratio of 0.59 mean the program saves lives?

It means the exposed group died less often. Moving from that to a causal effect of the program requires ruling out that the two groups already differed before the intervention, which this study cannot do.

Why were there more psychiatric hospitalizations in the group that received contingency management?

The simplest explanation, and the one the authors themselves put forward, is that a patient seen often in outpatient care is a patient whose decompensations get noticed.

Does this generalize beyond the Veterans Health Administration, for instance to France?

The delivery model itself does not: contingency management is available in only a small number of health systems worldwide, France among them.

What would it take to settle the question?

A randomized trial with follow-up long enough and a sample large enough to observe deaths. Given the number of events required, this would not be an easy trial to run.

Is a standardized difference of minus 0.63 a large effect?

Taken alone, it would correspond to a moderate effect. But the confidence interval runs from minus 1.11 to minus 0.14, which covers everything from a clear effect to a marginal one, and the certainty assigned to this…

What does 85% heterogeneity actually mean?

That the spread of results across trials far exceeds what chance alone would explain. The interventions, populations and scales differ too much for a single average to represent them faithfully.

Could exercise trigger a manic switch?

The review did not test this. It reports that no adverse event was recorded across the seven trials, all conducted with low- to moderate-intensity activities, and its discussion recalls earlier observations of…

Why is the effect size largest for anxiety?

Because only three trials measured it. Estimates from small pools are unstable and tend to overstate the effect. This is the most appealing result of the review and the least solid.

Can the identified modalities be used to prescribe a regimen?

No. These modalities emerge from comparisons between trials, not from randomization between formats. They can guide the design of a future trial, they do not fix a dose.

Does a drug that is no longer reimbursed lose its marketing authorisation?

No, the two are separate. In the French example, the marketing authorisation for donepezil remains in force and the drug is marketed, for the symptomatic treatment of Alzheimer’s disease in its mild to moderately severe…

Is a Cochrane review from 2018 still usable?

It remains the reference synthesis on this drug, but its corpus stops at 20 May 2017 and it has not been updated. Its method and calculations are not out of date, its body of literature is.

Does a statistically significant result mean a noticeable benefit?

No. Significance indicates that the observed gap is hardly compatible with chance, it says nothing about its size. With more than a thousand participants, a small gap becomes detectable.

What should I tell a family who asks why donepezil is no longer reimbursed?

In the French example, that the Haute Autorité de santé concluded in 2016 that the medical benefit was insufficient to justify coverage by national solidarity, and that the government drew the consequences through two…

Does the Cochrane review on donepezil justify ending its reimbursement?

No, and saying so would be a misreading. The review measures effects, it does not take a position on reimbursement policy.

Should donepezil be stopped in a patient who has been taking it for years?

The review does not answer this question. It covers trials of at least twelve weeks comparing donepezil with placebo or with another dose, most of them over six months or less; stopping a long-term treatment is not the…

Which donepezil dose should be used if treatment is continued?

The answer is less clear-cut than is often said. In three studies at 26 weeks, 5 mg/day did slightly less well than 10 mg/day on the ADAS-Cog, but not on the MMSE or the SIB, and it did slightly better on quality of…

Does the MM120 lysergide trial change the treatment of generalised anxiety disorder?

No. The trial is a phase 2b study, the dose-finding stage before phase 3 pivotal trials, and no active comparator allows the compound to be placed relative to available treatments.

Does functional unblinding mean the LSD trial result is false?

No, and that confusion should be avoided. It means the trial cannot distinguish the share of the effect due to the compound from the share due to the participant’s expectation.

Why did the 25 µg and 50 µg doses of MM120 not work?

They do not separate from placebo in this trial, with −1.2 and −1.8 points at week 4 and intervals that cross zero, which is not the same as the absence of any effect: the sample size was calculated to detect a…

Is an effect lasting twelve weeks after a single dose of lysergide credible?

It is the most interesting result of the trial and the one that calls for the most caution.

How much do sponsor conflicts of interest matter when reading this trial?

They matter as a weighting factor, not as grounds for disqualification. Nine of the twelve named authors are employees of the sponsor, the statistician is a paid consultant to it and the sponsor declares that it was…

Why use midazolam rather than placebo as the comparator in ketamine trials?

Because an inert solution reproduces nothing of the subjective experience of ketamine, which weakens blinding and leaves fully open the possibility that the observed effect is a non-specific sedation effect.

Why 84 patients when the meta-analysis reports 649 participants?

Because 649 is the size of the corpus, not that of the analyses. The GRADE table of the publication gives, for each outcome, the number of participants and trials actually pooled: 84 patients and three trials for the…

Is the Beck Scale for Suicide Ideation result negative?

No. The initial difference of 4.30 points was significant at the conventional threshold, and it stops being so when one trial out of the three in the analysis is removed.

How can a statistically significant result have only moderate GRADE certainty?

These are two different questions. The p value and the confidence interval describe the precision of the estimate within the available data; GRADE certainty describes how much confidence can be placed in that estimate…

Should the risk of derealisation lead to ketamine being withheld?

That is not what the review says, since it reports a frequency, not a severity or a duration.

Do these results apply to intranasal esketamine?

Nothing in this corpus allows it. The ten trials concern ketamine given almost exclusively intravenously, and in its racemic form in the trials that specify the form.

Is a two-point MMSE difference clinically noticeable?

Not necessarily in a given patient. It is a mean difference between two groups on a 30-point scale, with a confidence interval running from about 0.75 to 3.43 points.

If cholinesterase inhibitors are no longer reimbursed, does that mean they do not work?

No, and the confusion is common. Take the French example: the delisting ordered by the order of 29 May 2018 rests on a medical benefit judged insufficient by the Haute Autorité de santé in October 2016, that is on the…

Should cholinesterase inhibitors be continued indefinitely in very severe Alzheimer’s disease?

The review includes patients of mild to very severe severity, but the comparison between stages, planned in the protocol, could not be carried out: there were too few trials, and the authors state explicitly that they…

Is the loss smaller if cholinesterase inhibitors are tapered gradually?

It is plausible but not demonstrated. Only two of the seven trials used gradual withdrawal, which allows no reliable comparison between the two modes.

Does stopping cholinesterase inhibitors increase adverse events or mortality?

The analyses were indeed carried out and show no difference, whether for adverse events, serious adverse events or mortality.

Is magnetic seizure therapy available in routine practice?

At the date of our verification, 13 August 2026, the publication did not document any availability outside the trial setting.

Does non-inferior mean just as effective?

No. It means that the trial was able to rule out a loss of efficacy greater than a threshold decided in advance, here fifteen points of remission.

Is the cognitive advantage of MST over ECT demonstrated?

For autobiographical memory, yes, in the sense that it is a pre-specified primary outcome, tested after non-inferiority by a procedure that controls the risk of statistical error, measured by independent raters, with a…

Is magnetic seizure therapy safer than ECT overall?

Not uniformly. The profile is broadly more favourable, with fewer memory complaints, less confusion, fewer headaches and faster recovery.

Why were remission rates so low in both arms of the CREST-MST trial?

22.5% and 27.8% are below the 50% on which the sample size calculation had been built.

Does complex PTSD need a different treatment from PTSD?

According to this overview, no, not first-line: the same trauma-focused psychotherapies work, including on negative self-concept and on interpersonal relationships, with effects described as moderate to large depending…

Is a stabilisation phase needed before trauma-focused therapy?

The question remains open, but it is not without data. The 2012 international guidance, drawn from a consensus in which 84% of 50 expert clinicians supported a three-phase approach, has been revised towards a…

A patient asks about MDMA, ketamine or cannabis for PTSD: what should I say?

That the data exist, that they have been taken seriously, and that they are not enough.

Why does this review not rank PTSD treatments?

Because it aggregates nothing. It is a narrative synthesis of 54 reviews, without quantitative pooling, without formal appraisal of the quality of the included reviews and without grading of confidence in the evidence.

Do these findings apply to military veterans or refugees with PTSD?

Not directly: reviews centred on these populations are explicitly excluded from scope, as are those on children, older adults or significant comorbid conditions.

Does this study justify combining two antipsychotics?

No. It describes a statistical association between certain periods of polytherapy and a lower risk of readmission in the same patients.

Does a within-individual design remove confounding by indication?

It does not remove the part that matters. Everything stable in a person disappears by construction, including factors nobody has measured. Nothing that varies at the same time as the prescription disappears.

Why are there no hazard ratios for antipsychotic combinations in this analysis?

Because the published abstract contains none. Precise values circulate with no identifiable source, they do not appear in the publication. A figure that cannot be shown is not cited.

Is psychiatric readmission a good outcome measure?

It is the best available in a claims database, and it has real clinical value: a patient who does not go back to hospital lives better. But it measures the organisation of care as much as the illness.

Does industry funding invalidate this study?

No, and that shortcut would be lazy. The data come from the SNDS, the design is relevant, the result goes in the same direction as earlier literature.

What do guidelines say about antipsychotic polypharmacy?

NICE, in its CG178 guideline published in February 2014, updated in March 2014 and still in force, advises against starting regular combined antipsychotic medication, other than for short periods such as a switch.

Does this network meta-analysis show that antidepressants are safe in bipolar depression?

No. It shows that the available randomised trials do not detect a difference in switch risk between antidepressants and placebo, over an exposure of a few weeks.

Should the top-ranked antidepressant be preferred to limit the risk of manic switch?

No, for two reasons. The first is methodological: a P-score rank does not measure safety, it orders estimates whose intervals overlap, and the top two ranks here each come from a single small trial.

Does a risk ratio of 4.53 for venlafaxine justify avoiding it in bipolar depression?

That figure is not enough on its own, since its interval runs from 0.47 to 43.25.

Why is trial duration a particular problem for antidepressant-induced mania?

Because the observation window, from 1.7 to 10 weeks depending on the trial, covers only the acute phase. The authors stress that the long-term risk remains uncertain and call for longer trials or observational data.

How do differing definitions of manic switch affect the results?

They push towards no difference. Depending on the trial, switch is defined by a Young Mania Rating Scale threshold, ranging from above 10 to 16 or more, by categorical DSM criteria, by an adverse effects scale or by the…

What does this study say about antidepressant monotherapy in bipolar depression?

Little, and the authors say so. Two thirds of the patients received the antidepressant as add-on to a mood stabiliser, and the monotherapy subgroup rests on fewer trials, and so on a less robust evidence base.

Should duloxetine be added for patients with an insufficient response to clozapine?

No, not on the basis of this work. The estimate, SMD −1.53 with a confidence interval of −2.44 to −0.63, comes from a single trial of 40 patients randomised over 16 weeks.

Why be wary of such a favourable result in resistant schizophrenia?

Because the magnitude is far greater than what is usually observed in the psychopharmacology of schizophrenia, and it appears in a population where the expected effects are smallest.

Is an indirect comparison in a network meta-analysis as reliable as a direct one?

It carries less weight. An indirect comparison links two treatments never set against each other in the same trial by going through a common comparator.

Is the tolerability of clozapine combinations reassuring?

No. The tolerability outcomes were analysed and are not neutral: clozapine causes more sedation and more weight gain than several comparators, and discontinuations for adverse effects are more frequent on topiramate…

What should I conclude if another meta-analysis reaches the opposite conclusion?

That the question remains open. This work does not close the debate on the strategies to adopt in treatment-resistant schizophrenia; it confirms the place of clozapine and adds combination estimates whose robustness…

Does a low GRADE level of evidence mean a guideline recommendation is wrong?

No, and this is the main confusion to avoid. GRADE describes the certainty of the effect estimate, not the soundness of the recommended course of action.

Who assigned the levels of evidence analysed in this review?

The guideline authors themselves. This point is often misunderstood. A document had to grade each of its recommendations explicitly in order to enter the corpus.

Is class A evidence the same as a high GRADE level of evidence?

No, and that is precisely the finding of the study. In the nomenclature used here, borrowed from the American cardiology societies, class A denotes a level of evidence, that of at least two randomised trials or a…

Do these findings apply to national psychiatry guidelines?

The corpus analysed is limited to four bodies: the American Psychiatric Association, the European Psychiatric Association, the World Federation of Societies for Biological Psychiatry and the World Health Organization.

Does this mean clinicians should stop following guidelines?

No, and the authors themselves do not conclude so. For the individual clinician, a guideline remains the best available synthesis of a literature that cannot be read in full.

What is the main limitation of this review?

It lies in the harmonisation of scales. The four bodies do not use the same rating scale, and the authors had to bring them down to a common vocabulary in order to compare them.

Does this trial show that brexpiprazole does not work in PTSD?

No. It establishes that combining it from the outset, at fixed doses of 2 or 3 mg per day, with sertraline 150 mg per day brings no measurable benefit at ten weeks, in a population whose analysis excludes responders to…

Why was the brexpiprazole plus sertraline trial not placebo-controlled?

Because the question asked concerns the combination, not the efficacy of brexpiprazole in its own right. All three arms receive 150 mg of sertraline.

Why were the earlier brexpiprazole trials in PTSD positive when this one was not?

No explanation is established. The authors state that they ran multiple post hoc analyses, on methodology as well as on patient characteristics, without finding a clear cause.

Is the psychosocial functioning benefit with brexpiprazole plus sertraline clinically usable?

Not as an argument for prescribing. It sat on the last rung of the testing hierarchy, which stopped at the primary outcome: its p value is therefore no longer protected against multiplicity.

Should brexpiprazole be stopped in a patient doing well on the combination?

A group trial does not dictate individual management. The reasonable approach is to reassess with the patient what can be attributed to the treatment, to consider gradual tapering if no benefit can be identified, taking…

What does a SNP-based heritability of 11.5% for suicide attempt mean?

That 11.5% of the variability of the phenotype, in this sample and with this definition, is explained by the common genetic variants measured.

Should the drugs flagged by this study be prescribed to patients at suicide risk?

No. None was evaluated against a suicidality outcome in this work: they come out of a repurposing analysis based on matches between flagged genes and pharmacological targets.

Does loneliness cause suicide, according to this genetic study?

The analysis designates it as a putative causal risk factor for suicidal ideation, through the convergence of three methods. Two reservations matter.

Do these genetic findings apply to patients of every ancestry?

Not equally. The authors include participants of European, African, Admixed American, East Asian, Central and South Asian, and Middle Eastern ancestry, and report significant variants in several of these groups, which…

How does a multivariate GWAS differ from a standard GWAS?

A standard analysis treats one phenotype at a time. The multivariate approach analyses them jointly and gains power when they are correlated.

Does this study show that adolescent girls tolerate ADHD medication less well?

No. It shows that, in this cohort, girls aged 15 to 17 start treatment more often than boys of the same age (72.8% against 54.2%) and that, across all age bands combined, girls stay on treatment on average 13.2 fewer…

Is ADHD medication discontinuation the same as poor adherence?

No, and the distinction is central here. The study observes the absence of any pharmacy dispensing for at least 90 days.

Is a median of 106 days from ADHD diagnosis to first medication abnormally long?

This delay describes the time elapsed between diagnosis and first dispensing in a given health system, with its waiting lists and its initiation pathways.

Do these Norwegian figures apply to young patients in other health systems?

The proportions and durations, no: access to care, the ways treatment is started and the dispensing rules differ.

Should follow-up be stepped up for girls in particular?

This study tests no intervention, so it cannot answer that. It shows where to look. Closer follow-up in adolescence, whatever the sex, is a reasonable clinical decision, but its benefit remains to be demonstrated.

Are esketamine and rTMS equivalent for treatment-resistant depression?

No. The study detects no clinically relevant difference, which is not a demonstration of equivalence.

Does rTMS outperform esketamine on every outcome?

No. It comes out ahead on the adjusted primary outcome and on the adjusted odds ratio for response. On crude rates, it is the weakest of the three arms, for response as for remission.

Does this result apply to all patients with treatment-resistant depression?

It applies to patients who had failed one to three lines of treatment, as recruited in the two original trials. The authors specify that “our results may not apply to more refractory cases”.

What does the study show about tolerability of esketamine versus rTMS?

Nothing. No tolerability outcome was analysed. This is not an absence of signal, it is an absence of analysis. Choosing on tolerability means going back to the safety data for each technique, not to this analysis.

Is a head-to-head randomised trial of esketamine and rTMS needed?

It would be decisive, and the authors explicitly call for one. In its absence, this work is the best evidence available, provided it is read as an observational and exploratory comparison, not as a trial.

Should the order of treatments in treatment-resistant depression change?

The work suggests not holding back neuromodulation and ketamine as a last resort. It does not provide an algorithm, and it does not compare sequential strategies with one another.

Why does lithium augmentation not appear effective in treatment-resistant depression?

Its estimate in this network is not distinguishable from the comparator (OR 0.71, 95% CI 0.28 to 1.83). That does not demonstrate that it is ineffective.

Does this treatment ranking apply to bipolar depression?

No. Patients with bipolar disorder were explicitly excluded, as were those with psychotic depression.

Is psilocybin effective for treatment-resistant depression?

Psilocybin does not reach significance in this network (OR 1.8, 95% CI 0.62 to 5.25), any more than ayahuasca does (OR 3.94, 95% CI 0.73 to 21.20).

Is an odds ratio of 12.86 for ECT credible?

It matches what the authors report, but it is very imprecise and it does not withstand the sensitivity analyses. It is a textbook case: the size of an effect and the strength of the evidence are two different things.

Is once-daily lithium as good as twice-daily dosing?

This study cannot say so. It finds no difference at 12 hours, in 41 patients for whom the abstract reports no randomisation, with no published equivalence margin.

Should the timing of serum lithium sampling change?

No. The sampling reference depends on the pharmaceutical form: in the French summary of product characteristics cited above, 12 hours after the dose for the immediate-release form, 24 hours for the prolonged-release…

Do these results apply to prolonged-release lithium?

The published abstract does not specify the formulation. A prolonged-release form flattens the serum profile by design, which shifts the question without removing it.

Is higher lithium signal in white matter a cause for concern?

Nothing allows us to say so. The result replicates earlier observations by the same team. No link with efficacy, with adverse effects or with any clinical marker was tested here.

Will lithium MRI reach routine clinical practice?

Not in the short term. It requires equipment and methodological development available in a few research centres. Its current value lies in answering pharmacological questions, not in following patients.

Does this meta-analysis show that psilocybin is ineffective for depression?

No. It shows that the gap between active and control arms is larger in psilocybin trials, and that this gap stems from the behaviour of the control arm rather than that of the active arm, since improvement on active…

By how much might the effect of psilocybin be overestimated?

The work does not allow this to be quantified. It establishes a gap between outcomes on the comparator, not a correction factor applicable to published effect sizes.

Were the differences between psilocybin, SSRIs and esketamine tested pairwise?

No. The authors report an omnibus test of moderation by trial class, significant for the control arms and for the between-arm gaps, not significant for the active arms. No pairwise p value between two classes is given.

Why do control arms in esketamine trials improve so much when the patients are treatment-resistant?

This is an observation the study reports without settling it. The authors note that esketamine, like psilocybin, is administered on site and in the presence of health care professionals, and that it produces immediate…

Can psilocybin be offered to a patient with depression outside a clinical trial?

In France, no: outside a research protocol, it cannot be offered. Elsewhere, the answer depends on the rules in force where you practise, a question this meta-analysis does not address.

Is the unblinding problem specific to psychedelics?

Nothing in this work allows that to be claimed, since only three classes were compared.

Should clinicians stop ordering p-tau217 in mild cognitive impairment?

No. It remains highly accurate for what it is used for, detecting amyloid pathology.

Can this biomarker signature be used in routine practice?

The multiplex platform used here is a research tool, and the publication does not report routine use of the signature identified.

Does a hazard ratio of 39.8 mean a forty-fold higher risk of dementia?

It should not be read that way. It compares patients in the third tertile of the score with those in the first, leaving out the middle tertile and with no defined cut-off, and its confidence interval runs from 9.6 to…

Do these findings apply to patients seen in a memory clinic?

The cohort is French and multicentre, which is uncommon and makes transfer to French practice easier in particular. The population is older, mean age 77.8 years, which is a good match for memory clinic patients.

Does lithium plus an antipsychotic reduce suicide risk by 85%?

No. That figure comes from an observational within-individual analysis, with a confidence interval running from 0.055 to 0.428. It indicates a direction, not a magnitude that can be carried over to an individual patient.

Why do between-individual and within-individual analyses give opposite results?

Because they do not answer the same question. The first compares different people, the second compares periods within the same person.

Do these Korean cohort results apply to routine practice elsewhere?

Partly. The methodological reasoning is universal. The ranking of the drugs, on the other hand, comes from a Korean population, with neither lamotrigine nor antidepressants in the model, which limits direct transfer.

Is an atypical antipsychotic alone enough to lower suicide risk in bipolar disorder?

The published abstract reports no result for atypical antipsychotics alone. What the authors state is that the reduction in risk is associated with them when they are combined with lithium or valproate.

Is synaptic density PET used in routine clinical practice?

Not on the basis of this publication, which uses it only within a research protocol.

Is schizophrenia a disorder of the synapse rather than of dopamine?

The study does not set these two levels against each other. It measures synaptic density and finds that, in the left hemisphere, its spatial distribution resembles that of certain neurotransmitter systems more than that…

Do antipsychotics damage synapses?

This study cannot settle the question. The sample is chronic and exposed over the long term, so the effect of treatment and that of the illness cannot be separated.

Why does the lack of correlation with MRI volume matter so much?

Because it challenges a common shortcut, the one that treats volume loss as the image of neuronal or synaptic loss.

Are twenty-nine patients enough for a synaptic PET study?

For a large group effect measured with a precise technique, yes, provided one goes no further.

Is this trial of online parent-led CBT for child anxiety positive or negative?

Negative on what it committed to measuring, positive and significantly so on the ten secondary outcomes.

Why not rely on the complete case analysis, which was significant?

Because it excludes the families lost to follow-up, a little under three in ten.

Is a standardised mean difference of 0.15 to 0.47 clinically meaningful?

These children are not drawn at random: all of them have at least one risk factor identified at screening.

Does it matter that some of the authors developed the programme?

It disqualifies nothing, and the links are declared precisely, including possible future royalties. But it weighs mainly on the outcomes that parents complete themselves.

Can this online parent-led programme be used in routine practice?

Not as it stands. It rests on a dedicated platform and on a profession, the Children’s Wellbeing Practitioner, defined within the NHS, and the publication does not document the availability of the programme outside the…

Can screening for anxiety at school create anxiety where there was none?

That is exactly the question raised by the signal observed in the total population.

Why did children not self-report any improvement after parent-led CBT?

The trial cannot decide between several explanations: self-report scales at the age of eight are not very sensitive to change and discriminate poorly, which the authors had already observed before the trial; the parent…

Can this school screening-to-intervention model be used outside England?

The concept can: a brief screen, feedback, remotely guided parent-led therapy. The organisation cannot be carried over as it stands, since it was built for the English school system and its workforce, and the authors…

Does an odds ratio of 2.32 mean the intervention works twice as well?

No. It is an odds ratio, not a risk ratio, and it concerns a switch in a binary screening status.

Does 27% uptake of screening invalidate the trial?

It does not invalidate the result obtained in participants, who remain randomised by school.

Can an observational study tell whether methylphenidate causes psychosis?

The authors explain that a randomised trial would be both unethical, since one arm would have to be denied an effective treatment, and impractical, since it would need to run for more than a decade to assess an effect…

Can methylphenidate still trigger psychotic symptoms?

Transient psychotic symptoms on psychostimulants are described, particularly with overdose or misuse. They are a reason to stop and reassess.

Should children with ADHD be treated earlier and for longer to prevent psychosis?

No, not on the basis of these data. The signal comes from a secondary analysis in a stratum whose size is not given in the article, without correction for multiple comparisons and without replication.

Does this result apply to lisdexamfetamine and other stimulants?

No. The exposure studied is methylphenidate, which accounts for more than 90% of the stimulant reimbursements recorded in this sample.

Why do the risk differences in this study look so large?

Because they are not to be read as a gap between two groups. The coefficient is the change in probability associated with one unit of exposure, defined as 30 mg of methylphenidate per day for the whole intervention…

Does the EPIsoDE trial show that psilocybin does not work for depression?

No. It fails to demonstrate that it works, which is different. The confidence interval of the primary outcome remains compatible with a real effect, and the authors themselves describe their trial as inconclusive rather…

Why not rely on the significant secondary outcome of the psilocybin trial?

Because it was not the trial’s decision criterion. The pre-specified testing procedure stops as soon as the primary outcome fails: the secondary p values are reported as nominal and uncorrected, and therefore do not…

Why did EPIsoDE use two different comparators, nicotinamide and low-dose psilocybin?

Because they do not serve the same purpose. Nicotinamide, chosen because niacin is not approved in the European Union according to the authors, functions in their words largely as an inert placebo.

What does the improvement seen at twelve weeks mean?

Nothing about comparative efficacy. By then, every participant had received at least one 25 mg dose, and there was no longer a reference group.

Does functional unblinding invalidate the results of psilocybin trials such as EPIsoDE?

It weakens the result without cancelling it. The authors’ descriptive analysis even suggests that unblinding of the first dose weighed little on the week-six outcomes, but it rests on very small subgroups, one of them…

Does lithium reduce the risk of suicide?

The randomised trials gathered here cannot demonstrate it, for want of a sufficient number of events.

Why not simply run a larger lithium trial on suicide?

It would take very large sample sizes and prolonged follow-up to observe enough events. The authors indeed recommend longer trials using standardised suicide risk assessment tools.

What does a non-significant odds ratio of 0.61 mean?

That the point estimate corresponds to a risk reduction, but that the data remain compatible with a range of values running from a large reduction to a moderate increase.

Why was suicidal ideation not meta-analysed?

Because the methods and measurement instruments differ too much from one trial to another to be pooled. No conclusion, in either direction, can be drawn on this outcome.

Should another mood stabiliser be preferred for suicide risk?

This study provides no comparison between drugs on this outcome. The question is handled with current guidelines and the patient’s profile.

Do GLP-1 receptor agonists increase the risk of suicide?

This review cannot answer that. It did not analyse this risk in the included studies.

Can GLP-1 receptor agonists be used to treat alcohol use disorder?

Not on current evidence. The only randomised trial conducted in alcohol use disorder, with exenatide, shows no difference from placebo on heavy drinking days.

Why might mood improve on a GLP-1 receptor agonist?

Two explanations coexist. One is indirect: weight loss and glycaemic control could improve mood, which the authors themselves put forward.

Why did this systematic review not include a meta-analysis?

Because the studies differ in their designs, from randomised trials to case reports, in their populations and in what they measure. Pooling these results would have produced a figure that was precise and misleading.

Is a plasma proteomic ageing clock test available for patients?

The measurements are performed on research platforms, SomaScan and Olink, within established cohorts. The source describes no test intended for routine practice and claims no clinical use.

Does a hazard ratio of 12.59 mean my patient’s Alzheimer’s risk is twelve times higher?

No. It is a comparison between the two extremes of the marker’s distribution within a cohort, a cell-type age gap above two standard deviations on one side, below minus two on the other.

Do astrocytes cause Alzheimer’s disease?

The design does not allow that claim. The model selects proteins associated with age, then observes their predictive value.

Does this study say anything about preventing Alzheimer’s disease?

No intervention analysis appears in this paper. The silence of the source on this point allows no conclusion either for or against the efficacy of any preventive measure.

Is virtual reality cognitive remediation available in routine clinical practice?

Not in routine practice. For now it belongs to specialised services and research protocols.

Why be wary of such a large effect size?

Because small trials often produce overestimated effects, and because the primary outcome is measured in the same virtual modality as the trained task.

Did the control group in the virtual reality trial really do something comparable?

Partly. Same headset and same scenarios, but without strategies, feedback or adaptive difficulty, and supplemented by free games.

Does virtual reality cognitive remediation work equally for bipolar disorder, depression and schizophrenia?

The trial enrolled bipolar disorder (28 patients), unipolar disorder (10) and psychosis spectrum disorders (24) together, on the basis of cognitive impairment.

Does this study refute the European safety signal of July 2023 on GLP-1 receptor agonists?

It provides a reassuring argument in a specific population and on a specific outcome, incident depression. It does not address suicidal thoughts, which were the subject of the signal.

Why does the depression risk with GLP-1 receptor agonists differ between DPP-4 and SGLT2 inhibitors?

Because a hazard ratio is always relative to something. A favourable association against DPP-4 inhibitors and a null one against SGLT2 inhibitors may reflect a modest benefit of GLP-1 receptor agonists, or a…

Can GLP-1 receptor agonists be prescribed to treat depression?

No. No psychiatric indication is authorised. The authorised indications concern type 2 diabetes and, for some drugs, the management of overweight and obesity.

Is the stronger association with longer treatment duration credible?

It is possible, but the patients still on treatment after a year are those who tolerate it and are doing better.

What should a psychiatrist tell the diabetologist about GLP-1 receptor agonists and mood?

That nothing in this study justifies asking for a GLP-1 receptor agonist to be stopped for a psychiatric reason, or asking for one to be started for a mood-related reason.

Does this study mean that clozapine is not superior to the other antipsychotics?

No. It shows that there is no evidence of superiority on a short-term symptom outcome, with confidence graded very low.

Should clozapine be offered sooner, or later?

Nothing here justifies delaying an initiation. The operational message concerns the rigour of the preceding step: two documented trials, at an effective dose, for long enough, with adherence verified.

How does this result sit alongside the cohorts reporting lower mortality on clozapine?

By holding both, without merging them. The Finnish FIN20 cohort, which follows 62,250 patients over twenty years, associates clozapine with the best mortality figures of all the molecules studied, with an adjusted…

A difference of 0.64 points on the PANSS, what does that represent?

Nothing perceptible. The scale runs from 30 to 210 points. Even taking the bound least favourable to clozapine, around four points, one stays well below what is visible in consultation.

Should this be raised with a patient already stable on clozapine?

Not spontaneously, and certainly not as a challenge to the treatment. In a stable patient, the question of comparative efficacy at the start of treatment no longer applies.

Is it simply that patients do not turn up for appointments?

That is one of the possible explanations, and these data neither confirm it nor rule it out.

Are psychiatric patients treated less for their diabetes?

Not according to this study. On the composite treatment outcome no gap appears, 22 studies, odds ratio 1.02, p=0.87. They even receive insulin more often, 1.52.

Should the psychiatrist prescribe the diabetes treatments?

No. The study does not address the division of roles and recommends nothing on the point.

Do these figures transfer to a given health system?

Not as they stand. The corpus is international and dominated by the United States, and the heterogeneity between health systems is extreme.

Is the disadvantage greater in schizophrenia?

No, and this is one of the most unexpected results. Schizophrenia is not significantly associated with any monitoring indicator, and neither is bipolar disorder.

Should low-frequency rTMS over the left prefrontal cortex no longer be used?

This work does not allow that conclusion. It reports, on four trials and by indirect comparison, an odds ratio of 0.35 with a confidence interval running from 0.04 to 3.46 and a p value of 0.356.

Why not refer patients to the technique ranked first?

Because that rank rests on two trials and 42 patients in total, with an interval running from 1.35 to 38.47.

Does this ranking apply to bipolar depression?

The depressive episodes included come from major depressive disorder and from bipolar disorder alike, pooled under the term depressive episode, and the publication gives no separate hierarchy by diagnosis.

Is a network meta-analysis worth a head-to-head trial?

No. It produces comparisons that nobody has actually run, under an assumption of similarity between trials. It is a valuable instrument for ranking hypotheses.

What does this work say about tolerability and adverse events?

Tolerability is one of the two primary outcomes, measured by the all-cause discontinuation rate across the 272 arms of the network, and no active strategy departs from sham stimulation.

Does this work say anything about cognition?

Little, and the authors present it as an exploratory observation. Five trials only in the network assessed cognitive domains, mainly executive function and working memory, with heterogeneous measures.

Almost one patient in two in clinical populations: can I transpose that figure to my own caseload?

No. The 44.7% aggregates clinical samples whose definition varies from one study to another, and whose individual prevalences, in the detailed table, range from 0 to 93%.

Does CPTSD appear in DSM-5-TR?

No. CPTSD is an ICD-11 entity. DSM-5-TR does not retain it as a distinct diagnosis. That is why a clinician working with DSM-derived tools may never meet the question.

Should the PCL-5 be dropped in favour of an ICD-11 aligned instrument?

The study does not compare these two case-finding strategies and does not measure their effect on management.

Does the absence of a gender difference mean that CPTSD affects men as much as women?

No. No difference was observed, which is not the same as a difference measured as nil.

Do estimates this dispersed not make the meta-analysis useless?

They change what it is for. Such a spread forbids reading the pooled prevalence as a point estimate, but it does not cancel the information: the work documents the size of the corpus, the presence of the phenomenon on…

Does this study mean that CBT is useless in adult ADHD?

No. It shows that the favourable signal seen on clinician-reported ratings at 12 weeks is not recovered on self-report. A failure to demonstrate is not proof that there is no effect.

Should we conclude that stimulants are superior to everything else?

They are the component whose benefit is best supported, which is not the same thing.

Should a discontinuation odds ratio of 1.43 rule out atomoxetine?

No, it should make you prepare the prescription. The benefit on symptoms is recovered on both sources of rating.

A patient asks me about transcranial stimulation, what should I say?

That a signal exists, and that it is fragile. Transcranial direct current stimulation does better than placebo on the scales rated by the clinician, without that being recovered in what the patient reports, and the…

Is a network meta-analysis worth a head-to-head trial?

It does not replace one. It estimates comparisons that have never been run, from an assumption of similarity between the trial populations. The component model adds an assumption of additivity.

Should esketamine no longer be prescribed?

No, and the paper does not suggest it. The effect is real, it points the right way, and the drug keeps its place in patients whose options can be counted on the fingers of one hand.

A result that is significant but below the threshold, what does that mean in practice?

That the difference between esketamine and placebo is probably not due to chance, and that it stays small. Statistical significance answers the question of existence, not that of size.

Where does the 6.5-point threshold come from?

From the protocols of the three first pivotal trials, where it served the sample size calculation, on the basis of phase 2 results and of a clinical judgement, as the authors describe it.

Do the most resistant patients get more out of it?

Nothing shows that. Five moderators were tested, resistance level, age, baseline severity, gender and class of the combined antidepressant, and none is significant.

Is a team that has been criticising esketamine for years credible to reappraise it?

The question is legitimate and the answer lies in the format. A registered report fixes the analysis plan before the results are known and has the journal approve it at that stage.

Can esketamine be prescribed to a patient with bipolar disorder?

Not within the approved indication. Where the European wording applies, that indication covers the treatment-resistant major depressive episode of moderate to severe intensity, in combination with an SSRI or an SNRI…

Does this study prove that esketamine protects against manic switch?

No. It is an observational comparison, and a hazard ratio is not an effect. The reduction observed at 180 and 365 days has a simpler explanation: clinicians do not offer esketamine to patients they judge unstable.

Does the absence of a significant difference at seven days mean the short-term risk of switching is nil?

No. An absence of significant difference is not proof that there is no effect. Over seven days, coded switches are rare, and the number of events governs the ability to detect a difference.

Does a hazard ratio of 0.44 justify offering esketamine in a suicidal emergency in bipolar disorder?

It is not enough. This is a composite outcome whose composition is not detailed in the abstract, which speaks only of suicide-related events.

Should anything be concluded from the result observed in women?

No, not at this stage. A contrast between subgroups counts only if the interaction is tested and reported, which does not appear in the abstract.

Is this a new network meta-analysis?

No. The authors revisit a network meta-analysis published in 2023 in The Lancet Psychiatry, whose 101 quantitative studies they carry forward, and they add a complementary systematic review covering April 2023 to…

Can the seven drugs be ranked against one another?

Not from the published abstracts. No numerical value in the 2026 abstract, the magnitudes appearing in the abstract of the 2023 meta-analysis: from 0.41 (95% CI 0.19 to 0.64) for olanzapine plus fluoxetine to 0.16 (0.03…

Does this work validate antidepressants in bipolar depression?

They are not among the seven drugs named with good confidence. The abstract states that several other treatments might be efficacious with very low to low confidence, without naming them.

What is actually licensed for this indication?

Only quetiapine carries a marketing authorisation in the depressive episode of bipolar disorder in the European Union, the exact wording of its section 4.1 being “for the treatment of major depressive episodes…

Does public funding settle the question of independence?

No, these are two different questions. The funding here is institutional and not industrial, which is a favourable point.

Are mental disorders really becoming more common, or are we simply diagnosing them better?

Both hypotheses remain compatible with these data. The rise in the age-standardised rate is real as a measurement, but its cause is not established.

Why first for disability and only fifth for the overall burden?

Because the overall burden adds the years lost to premature death to the years lived with disability.

Does 1.17 billion cases mean 1.17 billion people?

No. The GBD counts prevalent cases, disorder by disorder. One person with two disorders is counted twice. The number of people affected is necessarily lower.

Can these data be used for one country in particular?

With caution. Each of the 204 countries is modelled, but an estimate produced by a global model does not replace dedicated national surveys. For a local argument, cross the two.

How is the gap between Viet Nam and the Netherlands to be explained?

The study does not explain it. Diagnostic recognition, exposure to risk factors and the quality of the source data probably all play a part, in proportions this design cannot estimate.

Is a prevalence ratio of 1.34 between siblings a lot?

At the scale of one individual it is modest, and it supports no prediction for a given patient.

Does the comparison between siblings prove causality?

No. It removes what siblings share, that is, part of the genetic background and the common family environment, which is already a great deal. It says nothing about what separates two children in the same family.

Why do eating disorders run the other way?

The study observes it, it does not explain it. Two hypotheses remain equally open: a genuinely higher frequency in well-off backgrounds, or faster ascertainment where people consult earlier and more readily.

Do these figures hold outside Norway?

The direction of the gradient, in all likelihood. Its magnitude, no. Norway has access to care that depends little on household means and low income inequality, yet its wealth inequality is among the highest in the OECD…

Should a family’s wealth really be asked about in consultation?

Not as an inventory, and never as a check. The useful question is functional: can the household absorb an unforeseen expense, does a debt weigh on daily life, is the housing secure.

Is this the first effective drug treatment for methamphetamine use disorder?

No. It is the first phase 3 trial of mirtazapine in this indication, and its primary end point is positive. It is neither the first positive trial, nor the first phase 3 trial conducted in this disorder.

Can mirtazapine be prescribed to a patient who uses methamphetamine?

Not in this indication under a marketing authorisation. Mirtazapine is licensed for the treatment of major depressive episodes in adults, and no medicine is approved for methamphetamine use disorder.

Why insist on the primary end point being self-reported?

Because mirtazapine produces recognisable adverse effects, drowsiness in 47% of patients against 33% on placebo, weight gain in 10% against 3%. A patient can therefore guess their group.

Two fewer days of use per month, is that clinically important?

Nobody can answer that with data. No validated threshold of clinical relevance exists for this end point. Two things can only be observed.

How widespread is methamphetamine use disorder?

Less evenly than the coverage suggests, and it cannot be quantified everywhere. Many national sources do not separate methamphetamine from the other amphetamines, neither for prevalence of use nor for seizures, which…

Would a longer treatment, or a higher dose, do better?

That is a hypothesis, not a result. The trial tested 30 mg daily for twelve weeks, and nothing in these data informs any other dose or any other duration.

Does this mean that suicide is genetic?

No. The study measures the share of the variability of a phenotype, in a population, attributable to common genetic variants.

Is there a test that can be used in the consulting room?

No. A score explaining 1.16% of the variance, with an area under the curve of 0.57, does not discriminate between two patients.

Should anything change in prescribing?

No. The molecules named are named because a gene flagged by the analysis appears in a pharmacological target database. That is a research lead, with no clinical efficacy data on a suicidality outcome.

What does a correlation of 0.88 actually change?

It supports an interviewing practice rather than a therapeutic decision. If ideation and behaviour shared exactly the same determinants, exploring one would inform you about the other.

Is a preprint reliable?

A preprint is work made public before peer review. Results can be revised, and figures sometimes move. Its consortium origin makes a substantive revision less likely, without ruling it out.

Does the plateau mean that no patient benefits from a higher dose?

No. It describes the median effect in a group. Some patients may respond above it, but aggregate data cannot identify them.

Why does methylphenidate show no plateau in adults?

The authors offer a possible explanation, the scarcity of trials at high doses in adults, which would prevent the curve from settling. They present it as a hypothesis.

Do these curves apply to long-term treatment?

They describe what double-blind randomised trials measured, and those are short by nature. The dose-effect relationship over several years, with growth, tolerance and adaptation, is not estimated here.

What should be made of atomoxetine?

No dose-effect relationship could be shown in the fixed-dose trials. The study neither supports nor discourages escalation in its case, and that is worth telling the patient.

Is this an argument against ADHD medication?

No, rather the opposite. The work describes curves that rise before they flatten, which gives a numerical landmark for not stopping too low.

Is galantamine superior to donepezil?

These data do not allow that to be asserted. The review compares galantamine only with placebo, and its authors state that direct comparison with the other drugs fell outside its scope.

Should a cholinesterase inhibitor be offered for a memory complaint or mild cognitive impairment?

No. This is the most directly usable conclusion of the review: no cognitive or functional gain demonstrated at two years, and a great deal more gastrointestinal adverse events and treatment discontinuation.

Why is this drug no longer reimbursed in some countries when the effect is demonstrated?

Because the two judgements do not bear on the same question. The review establishes that an effect exists and that it crosses the lower bound of a relevance threshold at six months.

Does the result on death change the benefit-to-risk balance?

It lightens it, it does not reverse it. A death rate of 1.3% against 2.3% at six months, with a confidence interval whose upper bound reaches 0.96, should be read as an absence of any signal of excess mortality rather…

How long should treatment be continued?

This review does not answer directly. Its summary of findings tables stop at six months in Alzheimer’s disease, a single trial runs to two years, and the authors explicitly report the absence of data beyond that.

Is memantine licensed at every stage of Alzheimer’s disease?

No. The licence covers moderate and severe disease. In the United States the drug is also widely used off-label in mild disease, and that is precisely the situation in which this review finds no demonstrated benefit and…

Is a gain of three points on a hundred-point scale clinically useful?

This is the question the review does not settle. It measures the effect and grades the confidence attached to it, it does not set the threshold at which the effect becomes worth having.

Should memantine be combined with a cholinesterase inhibitor?

The benefit of memantine is found whether or not the patient is taking a cholinesterase inhibitor, and the review reports that adding memantine to established treatment also results in less deterioration than placebo.

What can be said about frontotemporal dementia?

Two trials and 133 participants, at low to very low certainty. There is no demonstration of efficacy, and the review reports no tolerability data specific to this aetiology.

And in vascular dementia?

A small cognitive benefit is probable, about 2 ADAS-Cog points, with no demonstrated effect on daily function or on the global rating. That is little, and it rests on two trials only.

Does this study say that no alternative works?

No. It says that none reaches the threshold of evidence to be routinely recommended as a viable alternative to clozapine, which is a different statement.

Why does the effect of glycine site agonists weaken under scrutiny?

Because the base is very narrow, 9 trials and 187 patients, because all but two come from the same research group, and because one of the authors of seven of those trials acquired intellectual property rights over…

Is repetitive transcranial magnetic stimulation useless in schizophrenia?

These data do not allow that conclusion. They show that the available literature on positive symptoms carries significant publication asymmetry and that the corrected mean effect is no longer significant.

What should be done in practice when the patient refuses clozapine?

That question falls outside the scope of the meta-analysis, which does not assess strategies for revisiting the decision.

Are these treatments available to patients?

Both hold a European marketing authorisation, restricted to patients who are non-carriers or heterozygous for ApoE ε4.

How can a result be statistically significant and of no clinical interest?

Statistical significance says that the observed gap sits poorly with chance. It says nothing about its size. With nearly 10,000 participants, a minute gap becomes detectable.

Does this review bury the amyloid hypothesis?

No, and saying so would go beyond the data. It shows that these antibodies, at this stage of the disease and over this horizon, produce no clinically perceptible benefit, despite the reduction in amyloid load reported…

Are amyloid-related imaging abnormalities serious?

They range from an asymptomatic finding on a monitoring MRI to symptomatic oedema and cerebral haemorrhage. The review documents a clear increase in oedema, part of it symptomatic.

Can these molecules be called safe, since mortality does not rise?

No. Certainty is high and that is reassuring on the heaviest events, but a confidence interval compatible with 26 more serious events per 1,000 does not exclude a modest excess risk, and cerebral oedema is genuinely…

Could a benefit appear later, or earlier in the disease?

This is the main argument put against the review, and it is not unreasonable. It remains a hypothesis: eleven of the seventeen trials stop at 18 months, and none provides data on intervention in the preclinical phase.

Should we stop offering psychotherapy in stimulant use disorder?

No, and the review suggests it at no point. It establishes at high certainty that these interventions reduce dropout, reduce the frequency of drug intake and lengthen the longest period of abstinence.

How can one judge that a large effect is unlikely?

By having a sufficient body of trials and a confidence interval compatible at most with a modest effect.

Why does continuous abstinence increase when point abstinence does not follow?

The two outcomes do not measure the same thing. Point abstinence is a state observed on a given date.

Is contingency management available in routine practice?

We found no inventory that would allow an answer supported by a figure. What the review documents is where its evidence comes from: most of the trials were conducted in the United States, and contingency management is…

Do these results hold for methamphetamine?

With caution. Trials concerning methamphetamine use disorder represent 10.9% of the body of evidence, against 73% for cocaine and crack. The review reports no separate analysis by substance in its abstract.

What is known about the harms of these interventions?

Almost nothing. Five trials out of 64 report effects related to the psychosocial intervention, and four of them state that no adverse events occurred.

Does this study call complex PTSD into question?

No. It examines the factor structure of the instrument used to measure it. The authors conclude that the instrument is adequate for assessing the two ICD-11 diagnoses, and they write of the model matching that…

Should the questionnaire be abandoned?

Nothing in this analysis suggests it. The authors describe it as a strong and brief measure, suitable for assessing the two ICD-11 diagnoses at the factor level.

What does insufficient reliability mean in practice?

That a subscale score varies too much, between items meant to measure the same thing, to carry a clinical decision on its own. With two items per dimension in the short version, one atypical answer moves the whole score.

Does the result hold for a translated version of the questionnaire?

Of the 57 included studies, most used a translated version, and the language of administration was tested as a moderator of factor loadings, with a negligible mean change.

Will the seven-factor model replace ICD-11?

That is not what the study says. The authors suggest that future iterations of the ICD formulation of the complex form should specify the affective hyperactivation and hypoactivation dimensions.

Is the tool at fault, or the way it was used?

The trial tests one tool used in one precise way. The qualitative evaluation identifies several converging obstacles: workload, difficulty finding the report inside the electronic record, the delay between the report…

Do these findings apply outside the English health service?

The trial was run in eight English National Health Service trusts, whose organisation differs from that of child and adolescent services in other countries.

Was the trial adequately powered?

It exceeded its recruitment target, 1,225 randomised against 1,210 planned, with power calculated at 90% for an absolute difference of ten points.

Does the result vary with age or sex?

The document consulted reports no subgroup analysis. That is an absence of analysis in this source, not an absence of difference: nothing can be concluded from it either way.

Why does a negative trial of this size get so little attention?

Because it offers nothing new to do. That is precisely why it deserves to be read: it saves the effort of deploying a measure whose benefit was looked for and not found.

Does this study weaken the case for clozapine in treatment-resistant schizophrenia?

No. It finds that no conclusive evidence exists for switching to clozapine after a single four-week non-response.

Should two antipsychotics be combined?

The combination shows a statistically significant but modest effect, at very low certainty, with an odds ratio of 1.93 for adverse events.

Why does electroconvulsive therapy show the largest effect without being recommended here?

Because that effect rests on five trials and 97 patients, at very low certainty. A large apparent effect on a thin sample is not proof.

What does very low certainty actually mean?

That the true effect may be substantially different from the estimated effect. This judgement is not about the quality of the meta-analysis: it aggregates the risk of bias in the trials, the imprecision of the…